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Design and Biophysicochemical Properties of Chitosan-Collagen-Calcium Phosphate 
Microparticles and Scaffolds for Bone Tissue Regeneration.  Major Professor: Joel D. 
Bumgardner, Ph.D. 
Due to limitations of bone autografts and allografts there is much research 
directed at designing synthetic bone grafts. In this work, collagen-chitosan-calcium 
phosphate microparticles and microparticle-based scaffolds were compared to their 
counterparts without collagen in terms of degradation, cytocompatibility (porosity and 
stiffness only for scaffolds). Microparticles exhibited 20% decrease in mass over 6 weeks 
and provided an optimal environment for 3-5 fold cell proliferation over 7 days-culture 
period. Although there was no effect of collagen addition to microparticles, all the 
formulations may be suitable as bone tissue fillers. Further, there was no difference 
between control and collagen scaffolds. In general, scaffolds exhibited 23% porosity, 0.6-
1.2 MPa Young’s modulus, 10-25% degradation over 4 weeks, and supported a 4-7-fold 
increase in osteoblast cell number over 7 days in culture.  While there is room to improve 














       




List of Tables                                                                                                                  viii  
List of Figures                                                                                                                 ix 




1.1  Clinical Problem Statement 1 
1.2  Hypothesis and Objectives 6 
1.2.1  Objectives 7 
1.2.2  Significance 9 
 
2 Background and Literature Review 
 
2.1 Brief description of skeleton and bones                                              10 
2.1.1 Bone classification                                                                           10 
2.1.2 Bone anatomy                                                                                  10 
2.2  Bone injury and repair                                                                       12 
2.3  Bone grafts                                                                                         16 
2.3.1  Autografts                                                                           16 
2.3.2  Allografts                                                                            16 
2.3.3  Synthetic bone grafts                                                          16 
2.3.3.1  Ceramics 18 
2.3.3.2  Polymers 20 
2.3.3.3  Composites 22 
2.4  Chitosan 30 
2.5  Calcium Phosphate                                                                           31 
2.6  Collagen 32 
2.7  Composite chitosan-collagen biomaterials 33 
2.8  Conclusions 37 
3 Materials and Methods                                                                                     39 
4       Results                                                                                                                  50 
5 Discussion                                                                                                            70 
6 Conclusions                                                                                                          84    








       
Appendices    
 
A.  Degradation, cell attachment & growth on microparticles   100 
 







































       
 
LIST OF TABLES 
 
 
Table                                                                                                                              Page 
 
 
1 Characteristics of bone grafts                                                                               28 
 
2 Physical and compositional properties of the chitosan-collagen-calcium phosphate          
composite microparticles                                                                                      52 
 
3 The change in mass of beads in PBS only vs. degradation solution respectively, 
after six weeks                                                                                                     54 
 
4 The change in mass of scaffolds fused with either acetic or glycolic acid for PBS 
+ enzymes and PBS degradation solution only, respectively, after four weeks  64 
 
5 Young’s modulus of various bone scaffolds                                                   78 
 
6 Proliferation of osteoblasts or osteoblast-like cells on bone scaffolds                81 
 

























       
LIST OF FIGURES 
 
 
Figure                                                                                                                            Page 
 
 
1 Digital images of composite chitosan-collagen-calcium phosphate  
microparticles                                                                                                 50                                                                                                                                                                                                     
 
2 Representative XRD spectra of composite chitosan-collagen-calcium phosphate  
microparticles compared with chitosan                                                             53 
 
3 Degradation of microparticles in PBS + enzymes                                    54 
 
4 Degradation of microparticles in PBS                                                               55 
 
5 % fibroblasts’ attachment on beads                                                             56 
 
6       % osteoblasts’ attachment on beads                                                                  56 
 
7 Fibroblasts’ proliferation on beads 57 
 
8 Osteoblasts’ proliferation on beads 57 
 
9 Fibroblasts’ viability on 25% collagen-chitosan-calcium phosphate       
microparticles after one week                                                                              58   
 
10     Digital images of composite chitosan-collagen-calcium phosphate scaffolds: full 
view and close up to show pore structure                                                            59 
 
11     Porosity of scaffolds made of chitosan, 10% collagen or 25% collagen and fused 
with either acetic acid or glycolic acid                                                                61  
 
12     Representative stress-strain curve for scaffolds                                                  62   
 
13     Young’s modulus in compression of composite scaffolds                                  63 
 
14     Degradation of scaffolds in PBS + enzymes                                                       65  
 
15     Degradation of scaffolds in PBS                                                                         66 
 
16     Osteoblasts’ attachment on scaffolds                                                                  67 
 







       
Appendices 
 
A. Degradation, cell attachment & growth on microparticles                                           Page 
Table 
1 Regression lines of the degradation of microparticles in PBS + enzymes       100 
 
2       Regression lines of the degradation of microparticles in PBS                         101                  
          3        Cell attachment on microparticles                                                                   101 
 
          4        Cell proliferation on microparticles on the last day of proliferation               102    
          5        Regression lines of fibroblasts’ proliferation on microparticles                      102 
Figure 
1       Degradation of microparticles in PBS + enzymes                                             100 
2 Degradation of microparticles in PBS (control)                                                101 
3 Regression for fibroblasts’ proliferation on microparticles                               103             
4 Fibroblasts’ viability on microparticles.                103 
 









6       Regression lines of the degradation of scaffolds in PBS +enzymes                 105 
 
7       Regression lines of the degradation of scaffolds in PBS                                  106 
 
8       Regression lines of the osteoblasts’ proliferation on scaffolds                         107 










       
Figure                                                                                                                           Page 
 
 
6 Young’s modulus in compression of composite scaffolds for ε=0.1                105 
 
7       Degradation of scaffolds fused with acetic vs. glycolic acid in  
PBS + enzymes                                                                                                           106 
  
 
8       Degradation of scaffolds fused with acetic vs. glycolic acid in PBS               107 
 
9       Regression analysis of osteoblasts’ proliferation on scaffolds                          108 
 
10     Osteoblasts’ viability on scaffolds fused with acetic acid                                 109 
 






























       




1.1 Clinical problem statement  
Over 1,500,000 bone graft operations are performed every year in the United 
States for the treatment of musculoskeletal injuries/diseases including bone fractures, 
painful vertebrae, missing teeth, trauma (e.g., craniofacial trauma), osteosarcoma and 
birth defects. 
1-3
 The gold standard for bone graft therapies is the patient’s own bone, 
which is called an autograft. Autografts are considered the “gold standard” by many 
surgeons because they exhibit osteoconductive, osteogenic and osteoinductive properties 
due to resident growth factors.
1,4-6
 However, an autograft involves a secondary surgery 
with donor site morbidity or pain and increased surgical time.
7
 Allografts are bone grafts 
which come from cadavers and, while they have osteoconductive properties, they have 
limited osteoinductive properties and availability.
1
 There is a need to develop synthetic 
bone graft materials for bone regeneration.  
Some of the synthetic bone graft substitutes are calcium-phosphate ceramic-
based. The advantages of these ceramics are: similarity to the mineral phase of bone—
making them osteoconductive—their ability to form direct bonds with the surrounding 
bone
 
and minimal immunological and foreign body reactions.
8   
The disadvantages of 
ceramics are: lack of osteoinductivity,
8   
brittleness and the difficulty to machine into 
complex shapes and porous constructs.
9
 While there has been much research and 
development with these materials, their clinical efficacy has been questioned based on the 
small sample size, lack of control or comparison groups in most studies and the absence 





       
Other synthetic bone graft substitutes are polymer-based: natural or synthetic. 
On one hand, naturally derived polymers, such as alginate, chitin, chitosan, hyaluronic 
acid, collagen etc. are known to support cell attachment, but have poor mechanical 
strength.
10   
On the other hand, synthetic polymers, such as poly(lactic acid), poly(glycolic 
acid), poly(lactide-co-glycolic acid), poly-hydroxyl-butarate, poly(ε-caprolactone) have 
relatively good mechanical strength (however, in the porous form required for a bone 
graft, their Young’s modulus is below the 10 MPa inferior limit of cancellous bone, e.g. 
PCL scaffolds
11
), tunable degradation rates and can be manipulated into desired shapes, 




Synthetic bone grafts can incorporate bone morphogenetic proteins (BMPs), 
which are growth factors belonging to the transforming growth factor beta superfamily.
14
 
BMPs (e.g., BMP-2 and BMP-7) can be added to osteoconductive graft materials like 
calcium phosphates and polymers to make them osteoinductive. BMP-2 was used in 
various therapeutic interventions such as bone defects, non-union fractures, osteoporosis, 
spinal fusion and root canal surgery.
14
 Recombinant bone morphogenetic osteoinductive 
substitutes
15





Tapered Fusion for the treatment of degenerative disc disease (DDD) in skeletally mature 
patients. The Infuse® Bone Graft was approved as an alternative to autogenous bone 
grafts for sinus augmentations, and for localized alveolar ridge augmentations for defects 
associated with extraction sockets.
16
 The Infuse® Bone Graft consists of a solution of 
recombinant human bone morphogenetic protein-2 (rhBMP-2) and an absorbable type I 
collagen sponge, which acts as a degradable scaffold for the formation of new bone. The 
Ti alloy LT-Cage
®
 Lumbar Tapered Fusion is intended to restore the degenerated disc 
4 
 
       
space to its original height. Not all components of the Infuse® system are biodegradable, 
as is the case of the LT-Cage
®
 or of the intramedullary nail used together with the 
Infuse™ Bone Graft to help heal the fractures of the tibia.
9
 Some of the contraindications 
of Infuse® include: known hypersensitivity to rhBMP-2, bovine Type I collagen or Ti 
alloy; placement in the vicinity of a resected or extant tumor in patients who are 
skeletally immature, or in patients with an active infection at the operative site.
17
 Along 
the same lines, the safety and effectiveness of this device during pregnancy or nursing 
has not been established.
17
 
In 2008 the FDA issued a Public Health Notification regarding life-threatening 
complications associated with rhBMP when used in the cervical spine.
18
 There have been 
several reports of complications, occurring between 2 and 14 days post-op, such as 
swelling of neck and throat tissue, resulting in compression of the airway and/or 
neurological structures in the neck; difficulty swallowing, breathing or speaking; and 
severe dysphagia following cervical spine fusion with rhBMP due to the anatomical 
proximity of the cervical spine to airway structures in the body. Safety and effectiveness 
of rhBMP in the cervical spine have not been demonstrated and rhBMP is not approved 
by FDA for this use.
19
  
Additionally, osteoinductive growth factors like BMP-2 are expensive (50 µg 
BMP-2 are $955, while 10 µg BMP-7 are $400
20
), are subject to a limited shelf life,
21
 
may have adverse effects like antibody formation and immunological reactions, 
especially in cervical spine surgery when the margin for error is minimal.
22
 Incorrect 
placement of the BMP-carrier can induce undesired ectopic bone formation in 





       
Another strategy to make bone graft materials osteoinductive is to add 
mesenchymal stem cells. Cell-based bone graft substitutes include Osteocel Plus, 
marketed by ACE Surgical Supply, Inc. It has been investigated for various procedures, 
such as spinal fusion and for intervertebral disc regeneration.
15
 The product contains 
living bone cells, including mesenchymal stem cells. It also contains a polymer scaffold, 
which helps to enhance and encourage bone growth.
15
 Currently, clinical studies for 
Osteocel Plus are ongoing.
24




While there are several bone graft substitutes available clinically, they are not 
optimal for healing and/or regenerating bone because of the high cost of using growth 
factors, high dosing of growth factors, low mechanical properties which require an 
external fixation device and unestablished safety and efficacy.
3
 While some of the 
characteristics of ideal bone grafts have been met: cytocompatibility, osteoinductivity, 
moldability, peripheric vascularization, handling in the operating room, degradability, 
there is still room for improvement. A good vascular supply is imperative for the 
successful integration of a bone graft. Histological analysis of bone grafts demonstrates 
only 2-3 mm of vascular invasion into the material.
25
 To increase and maintain the 
vascular supply and to avoid necrosis at the core
26
, a blood vessel may be implanted or 
vascular channels and necessary growth factors may be incorporated into the scaffold.
25
 
Two characteristics to consider when evaluating bone grafts are stiffness and 
degradation. Although both are desired, stiffness is inversely proportional to degradation 
or polymer chain scission
27
 below the glass transition temperature of chitosan
28
, so the 
right balance has to be achieved. Some bone grafts have the Young’s modulus of cortical 
bone, but show low degradation in vitro after six weeks (12%) and in vivo after one 
6 
 
       
month.
29
 Other bone grafts may have compressive strength close to that of bone, but 
biocompatibility has not been  assessed.
30
 Further, other bone grafts may even replace 
cancellous bone due to Young’s modulus at lower limit for cancellous bone, but are 
brittle,
31
 while other bone grafts have Young’s modulus too high even for cortical bone 
replacement and are brittle.
32
 
Chitosan, a polysaccharide from the exoskeleton of crustaceans, is one of the promising 
bone graft biomaterials due to its attractive properties: osteoconductivity, biocompatibility, 
non-toxic and non-acidic degradation products.
33-39
  Chitosan also promotes wound 
healing, is mucoadhesive, antibacterial and moldable into three-dimensional (3D) 
scaffolds, can deliver antibiotics and bone morphogenetic proteins (in case the latter 
become cheaper in the future for treatment of a larger population).
33-39
  
To address the limits of autografts and allografts, our research group had 
previously developed composite co-precipitated chitosan/nanohydroxyapatite 
microsphere-based scaffolds as bone graft substitutes, which may also be used to deliver 
drugs locally.
40-42
 The 3-D scaffolds mimic the porous architecture of cancellous bone 
and have good biocompatibility with osteoblasts, supporting new bone ingrowth in vitro 
and in vivo.
40,41
 Young’s modulus (9.3±0.8 MPa) approached the values for cancellous 
bone (10-2000 MPa).
43
 The microspheres/microparticles or scaffolds can be loaded with 
antibiotics and/or growth factors to enhance osteoconductivity and biocompatibility at 
complex fracture sites, such as comminuted fractures and segmental bone defects. 
42
 One 
drawback of these scaffolds is a slow degradation profile,
40-42
 that can be attributed in 
part to the high degree of deacetylation (DDA). The high DDA may limit the bone 





       
We would like not only to maintain the desirable mechanical, cytocompatible or 
osteoconductive characteristics of chitosan-calcium phosphate microsphere-based 
scaffolds, but also to increase degradation and tissue ingrowth characteristics of the 
scaffold. This was achieved by adding a more degradable polymer to the composite 
composition. Collagen is a biocompatible and degradable natural polymer that can be 
easily combined with chitosan since both are soluble in dilute acids. Additionally, the 
inclusion of collagen will help to mimic the native bone extracellular matrix since 
collagen is a major constituent of bone along with the calcium phosphate mineral. We 
envision/hypothesize that adding collagen to our chitosan-calcium phosphate composite 
will improve degradation of the scaffold material without compromising initial 
mechanical properties. 
1.2 Hypothesis and objectives 
Our goal is to develop a scaffold that maintains mechanical strength during the 
first 4 months with increased degradation over time. The 4 months are chosen knowing 
that the reparative phase of bone healing takes around 18 weeks.
45
 Further, we would 
like the scaffold to degrade completely within 13 months because the remodeling phase 
and maturation of bone takes up to 54 weeks.
46
 This proposal would allow the native 
bone to regenerate and fill the void. 
Our research approach is to incorporate collagen in a chitosan-based composite to 
make a more biomimetic construct, composed of collagen, chitosan (a natural polymer) 
and a mineral, calcium phosphate. Chitosan, which contains glucosamine, mimics the 
glycosaminoglycan-components of the extracellular matrix, can actively direct the 
behavior of cells to facilitate regeneration of bone, is osteoconductive, biocompatible, 
mucoadhesive, antibacterial, moldable into three-dimensional (3D) scaffolds and has non-
8 
 
       
toxic and non-acidic degradation products.
33-39
 Calcium phosphate mimics the chemical 
structure of native bone mineral and provides mechanical strength due to its ceramic 
structure. Collagen type I will provide an additional biomimetic component to the 
composite because it is the most prevalent protein in the extracellular matrix of bone and 
is also biodegradable.
47
 Collagen concentration was chosen as 25% because this value is 
almost constant with age in tibial trabecular bone.
48
 10% collagen was chosen arbitrarily 
as an intermediate concentration between 0 and 25%. 
We hypothesize that the incorporation of collagen type I into chitosan-
calcium phosphate composite microspheres increases the degradation rate of the 
chitosan-calcium phosphate microspheres and microsphere-based scaffolds. 
Furthermore, we hypothesize that incorporating collagen type I into chitosan-
calcium phosphate microspheres will increase the compatibility of microspheres 








Prepare and characterize composite collagen-chitosan-calcium phosphate 
microparticles. 
a)  Incorporate collagen into chitosan-calcium phosphate microparticles (10 
mass% and 25 mass%) via a drip co-precipitation method. 
b)  Determine the amount of type I collagen within the composite collagen-
chitosan-calcium phosphate microparticles. 
c)  Determine the amount of calcium phosphate within the microparticles. 
d)  Characterize the composite collagen-chitosan-calcium phosphate 
9 
 
       
microparticles for shape using digital microscopy; for crystallinity via x-ray 
diffraction spectrometry. 
Objective II 
Characterize the in vitro degradation profile and cytocompatibility of composite 
collagen-chitosan-calcium phosphate microparticles.  
a)  Determine the percent change in mass of the composite microparticles over 
a six week-period in a lysozyme-collagenase solution as compared to plain 
chitosan microparticles. 
b)  Determine the percent cell attachment on the surface of the 
composite microparticles as compared to chitosan-calcium phosphate 
microspheres. 
c)  Determine the proliferation of cells on the surface of the composite 
microspheres quantitatively as well as qualitatively as compared to 
chitosan-calcium phosphate microspheres. 
Objective III 
Characterize the porosity, and mechanical compressive properties of 
composite scaffolds based on fusion of collagen-chitosan-calcium 
phosphate microparticles using acetic acid and glycolic acid.  
a)  Determine the porosity of the scaffolds via Archimedes’ principle. 
b)  Determine Young’s compressive modulus of the scaffolds via 
compression testing of hydrated constructs. 
Objective IV 
Characterize the in vitro degradation profile and cytocompatibility of composite 
collagen-chitosan-calcium phosphate scaffolds.  
10 
 
       
a)  Determine the percent change in mass of the composite scaffolds over a 
month-period in a lysozyme-collagenase solution as compared to chitosan-
calcium phosphate scaffolds. 
b)  Determine the percent cell attachment on the surface of the 
composite scaffolds as compared to chitosan-calcium phosphate 
scaffolds. 
c)  Determine the proliferation of cells on the surface of the composite 
scaffolds quantitatively, as well as qualitatively, as compared to 
chitosan-calcium phosphate scaffolds. 
1.2.2 Significance 
 
We propose that the fabrication of composite chitosan-collagen-calcium 
phosphate microspheres using a co-precipitation method will result in a bone graft 
substitute material that will be effective at healing the bone defect.  The incorporation of 
collagen would make the composites more compatible (since bone is composed of 
collagen) and help increase the degradation rate of chitosan scaffolds without losing 
initial mechanical strength or the overall osteoconductivity of the polymer-ceramic 
composite. This preliminary research is significant as the results would provide data to 
support the potential use of a composite collagen-chitosan-calcium phosphate micro-
particle system as a tissue filler or part of bone graft material (mimicking cancellous 









       
CHAPTER 2: BACKGROUND AND LITERATURE REVIEW 
 
 
2.1 Brief description of skeleton and bones  
Bones are organs of the skeletal system.
49
 Bone tissue, one of the specialized 
connective tissues, is characterized by a mineralized extracellular matrix.
50
 The 
mineralization of the matrix is the reason why bone is an extremely hard tissue that is 
capable of providing support and protection to the body.
50
  
 2.1.1 Bone classification  
Bone can be divided in two major types: cortical and cancellous. Cortical bone 
forms the outside of the bone and is a compact and dense layer, while cancellous bone 
forms the interior of the bone and consists of trabeculae (thin, anastomosing spicules of 
bone tissue), weaved in a sponge-like meshwork.
49
 The spaces within the meshwork are 
continuous and are occupied by marrow and blood vessels in living bone.
49
 Cancellous 
bone is typically found at the core of cuboid bones, such as vertebral bones in the spine, 
and at the ends of the long bones, such as the femur or tibia.
51
 
 2.1.2 Bone anatomy  
 The mineral in the extracellular matrix of bone is calcium phosphate, mainly in 
the form of hydroxyapatite crystals, Ca10(PO4)6(OH)2.
50







 Both can be mobilized from the bone matrix and taken up by the 
blood as needed to maintain normal levels.
50
 At the molecular level, the mineralized 
collagen fibrils of bone are made up of strings of alternating collagen molecules and 
hydroxyapatite, HA crystals, which appear in stair-step configuration.
52
 When pressure is 
applied to the fibrils, some of the weak bonds between the collagen molecules and HA 
crystals break, creating small gaps in the fibrils.
52
 The gaps spread the pressure over a 
broader area and protect other, stronger bonds within the collagen molecule itself, which 
12 
 
       
might break if all the pressure were focused on it.
52
 The stretching between fibrils lets the 
tiny HA crystals shift position in response to the force, rather than shatter, which would 
be the likely response of a larger crystal.
52
 Hydroxyapatite crystals are chalk-like
52
 and 
have 30 nm in length and about 2 nm in thickness.
53
 Hydroxyapatite significantly 
enhances the tensile modulus and strength of bone compared with a tropocollagen 
molecule alone.
54
 The stiffening effect depends on the thickness of the mineral crystal 
until a plateau is reached at 2 nm.
54
  
As previously mentioned, bone matrix contains type I collagen (90%) and, in 
small amounts, a number of other types of collagen (i.e., types V, III, XI and XIII).
50,55
 
Other proteins that constitute the ground substance of bone are present, such as 
proteoglycan molecules (which contain a core protein with various numbers of covalently 
attached side chains of glycosaminoglycans), multi-adhesive glycoproteins, bone-specific 
vitamin K-dependent proteins, growth factors and cytokines.
50
 The inorganic part of bone 
consists of calcium carbonate, magnesium, sodium, sulfate, potassium, chloride, nitrogen, 
fluoride and 20% water.
55,56
 
There are five types of cells. Firstly, osteocytes are cells found within spaces 
(lacunae) in the matrix.
49
 Each osteocyte extends processes to communicate with cell 
processes of neighboring osteocytes through gap junctions.
49
 Bone depends on osteocytes 
to maintain viability.
49
 Secondly, osteoprogenitor cells are cells derived from 
mesenchymal stem cells, which give rise to osteoblasts.
49
 Thirdly, osteoblasts are cells 
that secrete the extracellular matrix of bone.
49
 Once the cell is surrounded by its secreted 
matrix, it is called osteocyte. Fourthly, bone-lining cells are cells that remain on the bone 
surface when no active growth occurs.
49




       
remain after the bone deposition ceases.
49
 Fifthly, osteoclasts are phagocytic cells, which 
remove bone or are present where the bone has been damaged or is being remodeled.
49
 
Bones are covered by periosteum, a sheath of dense fibrous connective tissue 
containing osteoprogenitor cells.
49
 Bones that articulate with neighboring bones possess 
synovial joints covered by hyaline cartilage.
49
 Bone cavities are lined by the endosteum, 
a layer of connective tissue containing osteoprogenitor cells.
49
 The medullary cavity and 
the spaces in spongy bone contain bone marrow.
49
 Mature compact bone is composed of 
cylindrical units called osteons or Haversian canals.
49
 The osteons are composed of 
concentric lamellae of bone matrix surrounding the central, Haversian canal, which 
contains the vascular and the nerve supply of the osteon.
49
 Interstitial lamellae are 
remnants of previous concentric lamellae between osteons.
49
 Because of this 
organization, mature bone is also called lamellar bone.
49
 Circumferential lamellae follow 
the entire inner and outer surfaces of the shaft of a long bone, appearing much like the 
growth rings of a tree.
49
 Perforating canals (Volkmann’s canals) are channels in lamellar 
bone through which blood vessels and nerves travel from the periosteum and endosteum 
to reach the Haversian canal, as well as connecting one Haversian canal to another.
49
 The 
blood that nourishes bone moves from the marrow cavity into and through the bone tissue 
and out via periosteal veins.
49
 Thus, the flow to bone tissue is essentially centrifugal.
49
  
2.2 Bone injury and repair 
  
In the US approximately six million bone fractures occur each year.
45
  Five to ten 
percent of all fractures will have insufficient repair.
45,57
 Worldwide, in 2000 it was 
estimated that 9 million new osteoporotic fractures occurred, of which 1.6 million were 
at the hip, 1.7 million were at the forearm and 1.4 million were clinical vertebral 
fractures.
58
 The Americas and Europe accounted for 51% of all these fractures, while 
14 
 
       
most of the remainder occurred in the Western Pacific region and Southeast Asia.
58
 
Osteoporosis and consequently, bone fractures take a huge toll: in Europe, the disability 
due to osteoporosis is greater than that caused by cancer (with the exception of lung 
cancer) and is comparable or greater than that lost to a variety of chronic diseases, such 
as rheumatoid arthritis, asthma and high blood pressure related heart disease. 
58
  
Regarding military injuries, the musculoskeletal combat casualty rate for a US 
Army Brigade Combat Team during operation Iraqi freedom was 34.2 per 1,000 soldier 
combat-years.
59
 Spine, pelvis, and long bone fractures comprised 55.9% of the total 
fractures sustained in combat.
59
 Open fractures comprised 5.0 per 1,000 combat-years.
59
  
Natural disasters also have a high incidence of orthopaedic trauma. For example, 
other than wound debridement, the most commonly performed procedure during the first 
three weeks after the 2010 earthquake in Haiti was fixation of long bone fractures, which 
constituted approximately one third of all surgical procedures.
60
 
For car accidents orthopaedic trauma, in a defined area of central Sydney from 
mid-1991 to mid-1994, 21.5% of all adult car occupants and 49% of pedestrians 
sustaining major injury suffered lower extremity long bone fractures.
61
  
For malignancies of the bone reported by the Surveillance, Epidemiology and End 
Results (SEER) program areas from 1975 to 1995, the average annual incidence rate was 
8.7 per million children younger than 20 years of age, comprising about 6% of childhood 
cancer.
62
 Bone cancer non-unions arise from this population with bone malignancies. 
A retrospective study of 120 consecutive patients treated by a single surgeon for 
delayed or failed bone healing with a direct current bone stimulator, showed 86.8%  




       




The cases of orthopaedic fractures listed above shows the potential market for 
bone grafts. In 2010, it was estimated that 600,000 bone graft procedures are performed 
in the United States annually, and roughly 2.2 million procedures are performed 
worldwide, which cost approximately $2.5 billion per year.
64
 
A fracture is a break in bone, which, in some cases, results in bleeding at the 
fracture site.
65
 The initial strength of the bone, the magnitude, direction and rate at which 
force is applied determine the extent of the fracture.
66
 Fractures can be caused by sudden, 
high impact forces or by low-level cyclic forces. 
66
 Sudden, high energy forces produce 
some of the most severe fractures: comminuted and segmental bone fractures.
67-70
 
Comminuted fractures have more than two fragments, while segmented fractures are the 
ones in which the bone fragment is completely separated from non-fractured bone by 
fracture lines.
70
 In closed (simple) fractures in which the skin is not breached, normal 
bone healing takes place. Bone healing occurs in three different stages: the early 
inflammatory stage (hematoma formation), the repair stage (the fibrocartilaginous and 
bony callus formation) and the remodeling stage. 
55,57,69,70
 When a fracture occurs, not 
only is there a discontinuity in the bone, but also in the surrounding vascular system.
66
 A 
hematoma forms at the fracture site and inflammatory cells and fibroblasts migrate to the 
fracture site due to prostaglandin and growth factor release.
66
 Next, granulation tissue is 
formed, vascular ingrowth is initiated and mesenchymal cells begin to migrate to the 
fracture site.
55,57,70
 In the repair stage, as the blood supply to the fracture area improves, 
osteoblasts secrete osteoid and a collagen matrix is formed.
66
 Four to six weeks after the 
initial fracture the periosteum undergoes intramembraneous ossification and a 
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fibrocartilaginous, soft external callus is formed. The internal osteoid mineralizes and the 
internal callus develops into woven bone. In the last stage of bone healing, the woven 
bone is replaced by cortical bone and the bone is restored to its original shape and 
strength.
55,57
 Bone remodeling can last for months to years and occurs where forces 
require it, as stated by Wolff’s law. 
55
 
In large comminuted or open compound fractures, the vascular supply to the bone 
tissue may be completely destroyed.  Segmental and comminuted fractures are at 
increased risk for the development of non-unions (no development between bone 
fragments) and for becoming infected and developing osteomyelitis.
67-71
 These two types 
of fractures are so discomforting because the blood supply to the fracture area is 
destroyed and necrosis of the bone can occur. These fractures can be caused by war 
injuries, motor vehicle accidents, gunshot wounds and crush injuries. 
67,68
 Normal bone 
healing does not occur in large fractures/injuries where the vasculature is destroyed. To 
treat these situations, bone grafts are used to fill in the gap and to help heal the bone in 
order to maintain normal geometry and size of the bone. 
The ability of bone to repair itself is lost in a critical size defect. Factors that 
cause critical size defects include non-unions, bone cancer and birth defects. The 
critical size bone defect in humans is not clearly defined, but usually a defect > 1cm 
is considered to be a critical-sized defect.
72 
The length of segmental bone defects 
ranges from 0.4 to 7.6 cm and depends on the anatomical location of the defect.
73
 
Usually, the treatment of critical size bone defects involves bone graft implantation in 
conjunction with internal fixation in addition to long-lasting therapies to restore bone 
continuity and stability.
74,75





       
2.3 Bone grafts 
Current treatment options for non-unions and bone defects include: autografts, 
allografts and synthetic bone grafts. 
2.3.1 Autografts are bone grafts which come from the patient’s body. Considered 
the “gold standard” by many surgeons, it has very good osteoconductivity and also great 
osteoinductivity due to its high content of resident growth factors.
6
  The disadvantages 
are: the higher morbidity of the donor site, the secondary surgical access in a remote 
location of the body in order to harvest the bone (hip, for larger quantities, chin or the 
back of the jaw).
6
  Autogenous bone grafts have shown to be some of the most 
predictable grafts in surgery
6
 and are highly dependent on the quality of the patient’s 
bone. 
2.3.2 Allografts are a close relative of the autograft, in that they are of human 
origin, usually from cadavers from a bone bank.
6
  Despite the lack of a secondary surgery 
for harvest and the osteoconductive properties, allografts have very little if any 
osteoinductive properties because they lack bone cells and exposed osteoinductive 
proteins.
6
  Thus, graft assimilation and maturation takes longer than with the autografts.
6
   
2.3.3 Synthetic bone grafts 
Due to the disadvantages of autografts and allografts, scientists have looked for 
alternatives with quicker recovery times, lower costs and reduced risks, such as synthetic 
bone grafts. In these, scientists have tried to tailor biophysical properties so that an ideal 
scaffold can result. 
In case bone fails to unite over a defect, a bone graft offers a framework on which 
cells can attach and proliferate.
76
 The sine qua non for success of bone grafts includes: 
1. Interconnective pores to promote osseointegration and vascularization77 
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2. Controlled biodegradability so that the tissue will eventually replace the 
scaffold 
3. Adequate surface chemistry to favor cell attachment, proliferation and 
differentiation 
4. Appropriate mechanical properties to match the intended site of implantation 
and handling 
5. No serious adverse effects 
6. Easy manufacture and sterilization 
7. Easy handling in the operating room45,76 
Porosity, as a physical parameter, should provide adequate space for cell 
migration and expansion and maintain the transport of nutrients and waste products.78 
Various percentages exist for 3D scaffold fabrication, with porosities ranging from 10 to 
97%.
79
 However, increasing the porosity decreases mechanical strength, so a balance has 
to be achieved between porosity and mechanical stability.
80
 Scaffold pores ought to be at 
least 50 µm to promote osteogenesis.
66
 
A scaffold ought to maintain mechanical strength during the first 4 months with 
increased degradation over time because the reparative phase of bone healing takes 
around 18 weeks.
45
 Further, the scaffold ought to degrade completely within 13 months 
because the remodeling phase and maturation of bone takes up to 54 weeks.
46
 This would 
allow the native bone to regenerate and fill the void. 
Cells respond to the chemistry, topography and surface energy of the substrates 
with which they interact.
45
 The material substrates should have molecules of the 
extracellular matrix and initiate the attachment of proteins of the right type, amount and 
conformation, which modulate cell functions.
81
 It was shown that hydrophobic 
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biomaterials promote the adsorption and retention of proteins like fibronectin and 
fibrinogen.
82
 Moreover, calcium-based ceramics dissolve and precipitate on their surface, 
forming a carbonate-containing hydroxyapatite layer, which is osteoconductive.
83
  
Scaffolds should have no adverse side effects like immunogenicity, cytotoxicity 
and tumorigenicity. 
45
 Scaffolds should be easy to manufacture and sterilize (without 
compromising properties) for mass production. Bone grafts should be easy to handle in 
the operating room, without preparatory procedures so that infections would be 
minimized. 
2.3.3.1 Ceramics 
Ceramic-based bone grafts include calcium phosphate, calcium sulfate, and 
bioglass, which can be used alone or in combination with other materials.  
Most of the ceramic-based bone graft substitutes currently available are calcium 
phosphates.
15
 Several types of calcium phosphates exist: tricalcium phosphate, synthetic 
hydroxyapatite, and coralline hydroxyapatite, and are available in pastes, putties, solid 
matrices, and granules.
15
 Such calcium phosphate products include Bio-Oss (Osteohealth, 
Inc, Shirley, New York) and OsteoGraf.
15
 Bio-Oss uses hydroxyapatite as a particulate 
while OsteoGraf uses HA as blocks and particulates.
15
 Vitoss (Orthovita, Inc) is a 
tricalcium phosphate available in the form of a solid piece, putties or pastes.
15
 ProOsteon 
is a unique product based on sea coral, which contains HA and is similar in structure to 
trabecular bone. Nevertheless, like many of the solid calcium phosphates, ProOsteon is 





 Scaffold Synthetic Cancellous is a non-load bearing calcium phosphate-
based Bone Void Filler (Orthovita Inc.) indicated for use in the treatment of surgically 
created osseous defects or osseous defects resulting from traumatic injury to the bone 
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(i.e., the extremities, spine, and pelvis).
9
 It can be administrated using a prefilled syringe.
9
 
The surgeon can use either a secondary syringe or the vacuum line to aspirate blood or 
marrow into the Vitoss-Filled Cartridge.
9
 Bone void fillers similar to Vitoss include 
Biosorb
®
 Resorbable Bone Filler (Science for Biomaterials) and chronOS™ (Synthes-
Stratec Inc.), although they are less porous.
9
 Similar to other β-TCP, Cross Bone is a 
resorbable, biphasic ceramic implant composed of 60% hydroxyapatite and 40% β-TCP 
in the form of granules used for bone reconstruction.
9
 Examples of calcium phosphate-
based bone grafts include: Actifuse (a silicate-substituted calcium phosphate), 
BoneSource, BoneSave, HydroSet (Stryker, Kalamazoo, Missouri), and OsSatura TCP 
from Integra Orthobiologics, Plainesboro, New Jersey (pure β-TCP; it forms a well-
defined interconnected porosity that provides a high level of osteoconductivity). 
15
 
Calcium phosphates are easily handled as putties or pastes, but do not have 
appropriate mechanical properties for load-bearing sites because they are brittle at high 
Young’s modulus (in the case of hydroxyapatite). One more important issue with calcium 
phosphates is that they can possess a slow degradation rate, which may vary from months 
to years or it might even be incomplete.
84
 
Calcium sulfate, also known as plaster of Paris, is biocompatible, bioactive, and 
resorbable after 30-60 days.
15
 Because of its rapid degradation it also rapidly loses its  
mechanical properties.
15
 Hence, it is a questionable choice for load-bearing 
applications.
15
 Calcium-sulfate bone grafts include: Osteoset, a tablet for use for defect 
packing which is degraded in approximately 60 days (Wright Medical technology, Inc.) 
and AlloMatrix, which is Osteoset combined with demineralized bone matrix, DBM. The 
latter is sold as a putty or an injectable paste.
15
 However, a 13.8%-19.0% incidence of 
self-limited and benign adverse reaction was reported to OsteoSet bone graft substitute, a 
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surgical grade calcium sulfate in a pure, uniform, crystalline form (Wright Medical)
85
, 
which spurs the quest for new materials or material combinations for bone grafts. As 
there is no known cell-mediated regulatory connection between the degradation of 
calcium sulfate cements and the new bone formation, there is a risk that degradation 
might be too rapid, causing a new space if bone formation is not fast enough.
86
 
Bioactive glass (in particular, bioglass) is a biologically active silicate-based 
glass.
15
 Its applications are limited by high modulus and brittle, but it has been used in 
combination with polymethylmethacrylate to form bioactive bone cement. It has also 
been used as a coating on metal implants in the form a calcium-deficient carbonated 
calcium phosphate layer, which facilitates the chemical bonding of the implant to 
surrounding bone. Products from bioglass include Biogran (developed by Orthovita and 
licensed to Biomet 3i, Implant Innovations, Inc, Palm Beach Gardens, Florida) and 
Novabone (NovaBone Products, LLC, Alachua, Florida).  
In conclusion, the advantages of ceramics for bone grafts are: similarity to the 
mineral phase of bone—making them osteoconductive—their ability to form direct bonds 
with the surrounding bone,
 
biocompatibility and minimal immunological and foreign 
body reactions due to the lack of proteins associated with them.
8   
The disadvantages of 
ceramics are: lack of osteoinductivity,
8 
brittleness, the difficulty to machine into complex 
shapes and porous constructs, and low degradation for the ceramics with Young’s 
modulus close to that of cancellous
29
 or cortical bone.
87
  
 2.3.3.2 Polymers 
Polymers used as bone graft substitutes for bone tissue engineering 
applications can be either derived from natural sources: polysaccharides such as 
alginate, chitin, chitosan and hyaluronic acid, or proteins such as soy, collagen, fibrin 
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and silk--or from synthetic sources: poly(lactic acid), poly(glycolic acid), poly(lactide-
co-glycolide), poly(ε-caprolactone) and polyhydroxybutyrate.10,88,89 On one hand, 
naturally derived polymers are known to support cell attachment but have poor 
mechanical strength.
10   
On the other hand, synthetic polymers have relatively good 
mechanical strength (however, in the porous form required for a bone graft, their 
Young’s modulus is below the 10 MPa inferior limit of cancellous bone, e.g. PCL 
scaffolds
11
), tunable degradation rates and can be manipulated into desired shapes, but 
may have undesirable acidic degradation products, which may stimulate an 
inflammatory reaction.
12,13
 Examples include: Cortoss (Orthovita, Inc, Malvern, PA), 
made of bis-glycidyl methacrylate; Open Porosity Poly(lactic Acid) polymer, OPLA, 
(TMH Biomedical, Inc., Duluth, MN), made of a PLA/PGA copolymer; Immix 
(Osteobiologics, Smith and Nephew, Memphis, Tennessee), made of a PLA/PGA 
copolymer as the base material and PGA fibers, Bioglass (a 45S5-type glass), and 
calcium sulfate as additives to vary stiffness; and Healos (Depuy Orthopaedics Inc, 
Warsaw, Indiana), an osteoconductive matrix made of cross-linked collagen fibers that 
are fully coated with HA through a proprietary 360 accretion process).
15
 Lastly, Ahn et 
al. produced highly porous and surface-roughened/layer-by-layer 3D poly(ε-
caprolactone) scaffolds with thickness of more than 2 mm with high osteoblast-like 
MG63 cell viability, increased ALP activity and calcium mineral.
90
 One of their  









       
 2.3.3.3 Composites 
Composite systems maximize the advantages of two or more materials, while 
minimizing their individual disadvantages. Three examples of bone void fillers available 
on the market are provided: 
1. Healos (DePuy Orthopaedics, Inc, Warsaw, Ind) is a polymer-ceramic 
composite consisting of collagen fibers coated with hydroxyapatite and 
indicated for spinal fusions,
15
 which is osteoconductive and stronger than 
collagen alone due to addition of hydroxyapatite, a crystalline form of 
calcium phosphate. However, neither does it bear loads, nor does it have a 
dual structure to mimic the cortical and cancellous lamellar composition of 
bone. All available bone graft materials are limited in the latter regard: they 
do not mimic the 3D bone architecture of bone. Using solely a cancellous 
bone replacement consists in the use of external fixation devices, which have 
to be removed surgically, while cortical bone replacements used as a stand-
alone may cause stress-shielding. 
2. The Vitoss® Scaffold Foam™ (Orthovita Inc., Malvern, PA), a bone void 
filler, consists of a mixture of β-tricalcium phosphate, β-TCP, and Type I 
bovine collagen in a hydroxyapatite carrier.
9
 Used alone, this product does not 




3. Integra MOZAIK™ Osteoconductive Scaffold (Integra LifeSciences 
Plainsboro Township, NJ ) is made of 80% tricalcium phosphate and 20% 
type I collagen; it resorbs at a rate consistent with the formation of new 
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bone
15
. Similarly, this product does not have osteoinductive properties, and, 
since most of it is made of β-TCP, it is brittle. 
Several research labs are investigating alternative bone grafts: Chen et al. 
developed a PLLA scaffold with apatite/collagen composite coating.
92
 PLLA scaffolds 
with apatite/collagen coating exhibited better Saos-2 cell viability than uncoated PLLA 
scaffolds or PLLA scaffolds with hydroxyapatite coating
92
. Similarly, Kim et al. 
produced porous poly(D,L-lactic-co-glycolic acid)/nanohydroxyapatite (PLGA/ HA) 
composite scaffolds, coated with HA in simulated body fluid, SBF. The PLGA/HA 
scaffolds exhibited higher osteoblast cell growth, alkaline phosphatase activity and 
mineralization than PLGA scaffolds
93
. Ciapetti et al. found that the HA-added poly(ε-
caprolactone)-based polymers obtained the best colonization by Saos-2 cells after 3-4 
weeks and that more mineral was formed on HA-added poly(caprolactone)-based 
polymers coated in simulated body fluid, SBF than on PCL-based polymers.
94
 Lickorish 
et al. found that a porous, collagenous scaffold, biomimetically coated with 
hydroxyapatite using SBF, supported L-929 fibroblasts and rabbit periosteal cellular 
attachment and proliferation (it is assumed that the scaffold is weak because the 
majority of the scaffold is comprised of collagen).
95
  MG63 osteoblasts attached to 
collagen-derived gelatin/hydroxyapatite (HA) nanocomposites to a significantly higher 
degree and subsequently proliferated more than those conventionally mixed gelatin-HA 
composites.
96
 The nanocomposite scaffolds retained less-crystallized and smaller-sized 
apatite crystals (~40 nm) and a more developed pore configuration than the 
conventional ones.
96
 Collagen beads can be formed by extruding collagen solution into 
chondroitin sulfate A solution.
97
 Subsequently, the collagen beads thus formed are 
soaked in SBF solution to form nanohydroxyapatite on the surface and mimic the 
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formation process of natural bone matrix, providing a substrate for cell growth and 
enhancing the osteoblast-like cell differentiation of MG63 cells.
97
 Further, MC3T3-
E1cells proliferated on poly-L-lactic acid (PLLA), chitosan and hydroxyapatite (HA) 
microsphere-based scaffolds (macroporosity >50%) and formed an extracellular matrix 
network, while differentiating into mature osteoblasts, as indicated by alkaline 
phosphatase activity.
98
 While no degradation was assessed, Young’s modulus of 0.42 
MPa indicated their use in non-load bearing applications.
98
 In spite of the promising cell 
growth (osteoblasts, in particular) and even increased ALP activity and mineralization in 
some cases, the mechanical properties constitute an issue that needs to be addressed so 
that the scaffolds may become load-bearing. 
Recently, a calcium phosphate/polyurethane with both HA and β-TCP 
composites was developed for weight-bearing implants.
29
 Although it reached high 
compressive modulus values which ranged from 2.5 to 3.6 GPa, this potential bone graft 
cannot be used to replace cancellous bone and may cause stress shielding. Although the 
clonal osteoblastic cell line, 2T3, isolated from murine calvaria shows the 
biocompatibility of the implants, both the in vitro (12% degradation after 6 weeks) and 
in vivo degradation in a rat model are low.
29
 The problem with the low degradation rate 
is that the bone defect is not completely healed, since the partly degraded scaffold-new 
bone combination may not be as stiff and cohesive as native bone itself. 
Chitosan, a natural-based nontoxic, biocompatible, and biodegradable polymer 
with anti-microbial activity, is also reported to promote osteogenic progenitor cell 
recruitment and attachment, facilitating bone formation.
38,99
 Chitosan and its derivatives 




       
cells and repairing cells.
38
 Recent studies further indicated that chitosan and its 
derivatives also are novel scaffold materials for tissue engineering and gene delivery.
38
 
One property of chitosan that must be taken into account when designing 
chitosan biomaterials is the degree of deacetylation (DDA). Chitin has no DDA or 0% 
DDA, while pure chitosan has 100% DDA.
66
 Chitosan materials with DDA close to 
50% are the most degradable in vitro and in vivo.
33,38,100
 Below or above 50% DDA, 
chitosan loses degradability due to the fact that its chains pack more closely together, 
giving it a more crystalline character.
66
 Chitosan with DDA>95% has been known to 
last for months. 
33,38,100
 
Chitosan has been modified or combined with other materials in bone 
regeneration. For example, lyophilized N,N-dicarboxymethyl chitosan-calcium 
phosphate sponges quicken bone wound healing in femurs of sheep and in humans 
undergoing apicectomies and dental avulsions.
101
 However, the surgical defect in sheep 
was filled with a tissue without the histoarchitectural characteristic of bone tissue and 
the dental defect was weakly load-bearing, so the bone graft is non-load-bearing.
101
 
Hydroxyapatite-chitin lyophilized gels were loaded with MSC-induced osteoblasts were 
reported to be osteoinductive and exhibited neovascularization and rapid degradation 
after 3 months in vivo compared to the chitin control.
102
 The imidazole-linked chitosan 
material promoted mineralization, induced bone formation and filled critical size bone 
defects with the apposition of trabecular bone in the femoral condyle of sheep.
103
 
Chitosan/tricalcium phosphate sponges incorporating platelet-derived growth factor 
(PDGF) induced new bone formation in a rat calvarial defect.
104
 Chitosan-alginate 
gel/mesenchymal stem cells/bone morphogenetic protein-2 composites were found to 
stimulate new bone formation when injected into a mouse.
105
 Even though most of these 
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chitosan gels and sponges stimulate bone formation, they still lack stiffness needed for 
load-bearing applications or the quality of the bone produced is poor (i.e. cancellous 




Other groups are also struggling with degradation of chitosan scaffolds: 3D-
bioplotted, cell-seeded tricalciumphosphate/chitosan/collagen and tricalciumphosphate 
/collagen scaffolds increased the amount of newly formed bone within ovine critical-size 
calvarial defects, but stiffness and biodegradation of materials are not appropriate for the 
application in cranio-facial surgery and have to be improved.
106
 
When compared to plain chitosan scaffolds, composite chitosan-hydroxapatite 
scaffolds exhibited rougher surface and greater surface area for cell attachment, about 3x 
higher Young’s modulus and increased pre-osteoblast proliferation.
107
 The chitosan-
crystalline calcium phosphate scaffolds were tougher and more flexible than what has 
been reported for pure calcium phosphate scaffolds.
107
  
Several researchers have investigated chitosan,
108-111
 and chitosan composites 
with calcium phosphate,
40,112-114
 beta-tricalcium phosphate (β-TCP) and gelatin 
crosslinked with glutaraldehyde,
115




 but the 
shortcoming of the materials is that their Young’s modulus was below that of cancellous 
bone. For collagen-based implants reinforced by chitin fibers values for mechanical 
strength were not reported, which may be low due to the collagen base material.
120
 
Macroporous HA/β-TCP nesting chitosan sponges exhibited higher Young’s modulus of 
15 MPa, but they are brittle due to high percentage of ceramics.
31
 Further, it was 
reported that Young’s modulus of nanocomposites of chitosan–hydroxyapatite–
polygalacturonan was 23.63 GPa, which is too high even for cortical bone replacement; 
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moreover, the composites can be brittle in nature due to HA.
32
 In another study by Li et 
al. 30/70 chitosan/n-HA composite had compressive strength of 119.86 MPa close to 
that of bone, but no cell studies were pursued.
30
 Lastly, cellulose derivatives-based 
scaffolds showed Young’s modulus and strength in the mid-range of human trabecular 
bone, but had low degradation: mass loss of 10-15% after 6 months.
121
 All in all, these 
studies show the lack of scaffolds with a Young’s modulus close to that of bone, that are 
also not brittle, slowly degrading and showing cell viability. 
Broadly, composite bone grafts  (with or without chitosan) have been shown to 
be osteoconductive,
15
 and osteoinductive when loaded with MSC-induced osteoblasts.
102
 
Composite grafts show high osteoblast,
29,90,92,94,96,97
 periostal and associated cells 
viability,
95









 and new bone formation in vivo.
102,103,105
 
Their main limitation is that they are non-load-bearing or no mechanical properties are 
observed. Some bone grafts have Young’s modulus of cortical bone, but show low 
degradation in vitro after six weeks (12%) and in vivo after one month.
29
 Some bone 
grafts may have compressive strength close to that of bone, but no biocompatibility was 
assessed.
30
 Further, some bone grafts have Young’s modulus at the lower limit for 
cancellous bone, but are brittle,
31
 while other bone grafts have Young’s modulus too 
high even for cortical bone replacement and are also brittle.
32
 A summary of bone graft 







       
Table 1. Characteristics of the classes of bone grafts. 
Bone graft type Pros Cons 
Ceramics:  
CaP, CaSO4, bioglass 
• osteoconductive 
• direct bonds with the 
surrounding bone 











• the difficulty to 
machine into complex 
shapes and porous 
constructs  
• low degradation for 
the ceramics with 















fibrin and silk 
 
• support cell 
attachment 
 





• Synthetic:  




• relatively good 
mechanical strength 
• good degradation 
rates 
• anatomical fit 
• undesirable acidic 
degradation products, 








with both HA and β-TCP  
• collagen fibers coated 
with HA 
• PLGA/HA scaffolds  
• Gelatin/HA  




• Chitosan/TCP sponges 
• osteoconductive15 

















   
• neovascularization102  
• rapid degradation102 







growth factor loading 






       
One strategy to improve tissue engineering scaffolds for bone grafts is through 
the use of microspheres. The microspheres when packed together like balls in a box, 
provide for complete interconnected porosity for cell/tissue ingrowth. The microspheres 
provide a stronger 3D network to improve mechanical loading, and serve as a negative 
template for bone formation and organization.
122
 
The ease of packing into various shapes also makes microsphere-based bone 
grafts attractive for filling irregular bone defects. Using this approach, Chesnutt et al. 
developed a co-precipitation method to form chitosan – calcium phosphate composite 
microspheres and then formed scaffolds by fusing the beads.
40
 The scaffolds were made 
with a chitosan with a high degree of deacetylation: 92.3%. The addition of 
hydroxyapatite to chitosan increased the surface roughness, the compressive modulus 
(by almost 3x), when compared to other chitosan-calcium phosphate composites or 
calcium phosphate scaffolds alone. Not only were the scaffolds stronger, but also they 
showed better osteoblast proliferation as compared to chitosan scaffolds.
40
 The Young’s 
modulus of these scaffolds, 9.3±0.8 MPa, was at the lower limit for cancellous bone. In 
the in vivo rat calvarial defect study, the scaffolds showed good osteoconductivity, but 
the in vivo degradation of scaffolds was low, which may have also limited bone tissue 
ingrowth.
41
 Chesnutt showed the potential of chitosan-calcium phosphate microsphere-
based scaffolds to serve as bone grafts through osteoblast proliferation, Young’s 
modulus at the lower range of cancellous bone, good osteoconductivity, but the material 
had a limitation: low degradation, attributed in part to the high DDA.
41
 
Consequently, the main focus of this study was to improve the degradation of 
these chitosan-calcium phosphate scaffolds, which may be used as cancellous bone 
replacement. One way to improve their degradation is to add collagen to the chitosan-
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calcium phosphate composite material. Degradation would increase, in part because 
collagen is highly degradable. The biomimetic nature of the composite would also be 
increased since collagen is the major ECM protein of bone which may further enhance 
its potential to serve as a bone graft substitute material.  
Since native bone is composed of mineral, collagen and glycosaminoglycans, the 
biomimetic composite scaffold was designed with calcium phosphate mineral, collagen 
and chitosan instead of glycosaminoglycans to mimic bone composition. The three 
building materials of the microspheres and the rationale for combining all these 
biomaterials into bone grafts will be further discussed. 
2.4 Chitosan 
Chitosan, a partially N-deacetylated derivative of chitin, is a natural linear 
polysaccharide derived from the exoskeleton of crustaceans.  Chitosan holds promise in 
biomedical research due to its attractive properties of osteoconductivity, biocompatibility, 
non-toxic and non-acidic degradation products, promotion of healing, mucoadhesiveness, 
wound healing properties, moldability into three-dimensional (3D) scaffolds, making it 
an ideal candidate for tissue engineering and drug delivery applications.
33-39
 Chitosan 
exists in various forms: microspheres, films, scaffolds, gels, bioactive coatings for 
orthopaedic and craniofacial implants, which support bone cell in-growth and is able to 
deliver antibiotics and bone morphogenetic proteins.
113





 and cross-linked chitosan microspheres 
124
 were 
used in bone regeneration, albeit for non-load-bearing purposes. 
In spite of its nontoxic degradation byproducts: saccharides and glucosamines 
which are incorporated into glycoproteins or excreted as CO2,
33
 chitosan’s slow 
degradation profile  due to the high degree of deacetylation, DDA, can limit the bone 
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growth within the scaffold and bone defect volume
44
, consequently restraining the use of 
chitosan as a bone graft for tissue engineering and drug delivery. 
The DDA and the molecular weight are two important properties of chitosan and 
are known to affect how chitosan will perform clinically.  It has been reported that 







as well as with the decrease in molecular weight of the 
polymer.
125,126
 The decrease in DDA reflects lower crystallinity.
 
Therefore, a lower DDA 
and molecular weight chitosan is a way to increase degradation. 
It has also been reported that the mechanical strength of chitosan decreases 
with the decrease in the degree of deacetylation
127,128
 and molecular weight of 
chitosan.
129   
Since the scaffolds are aimed at a load-bearing application, the lowest DDA 
and molecular weight should not be chosen, which brings up the issue of finding a suitable 
low DDA and molecular weight, which will provide some mechanical strength and 
increase degradation. 
On the one hand, chitosan has immense potential as an orthopaedic biomaterial 
41,42,130-134
. On the other, the low degradation rate of chitosan microsphere-based 3D 
scaffolds limits its use in tissue engineering and drug delivery applications. To increase 
degradation, collagen was added to the microparticles because it undergoes rapid 
degradation upon implantation.
44
 Calcium phosphate, which is osteoconductive, was 
added as well to mimic the major component of the inorganic phase of bone.
42
 
2.5 Calcium phosphate 
Calcium phosphate is added to the microparticles because it is osteoconductive, 
has good strength and hardness.
66
 Calcium phosphates have been used in implant 





       
The reason for combining bioactive ceramics with degradable polymers, such as 
chitosan, is to create scaffolds that maintain the bioactivity and strength of calcium 
phosphate. 
2.6 Collagen 
Collagen is the most widely found protein in mammals (25% of our total protein 
mass) and is the major provider of strength to tissue.
140
 A typical collagen molecule 
consists of three intertwined protein chains that form a helical structure.
140
 These 
molecules polymerize together to form collagen fibers of varying length, thickness, and 
interweaving pattern (ropelike structures, meshes or networks).
140
 The predominant form 
used in biomaterial applications is type I collagen, which is a "rope-forming" collagen 
and can be found almost everywhere in the body, including tendons, the endomysium of 
myofibrils and the organic part of bone. 
141
 The basic unit of the extracellular matrix 




Collagen is resorbable, non-toxic and excellent for attachment and biological 
interaction with cells.
143
 Moreover, collagen may be processed into a variety of formats, 
including porous sponges, gels, and sheets, and can be cross-linked with chemicals to 
make it stronger or to alter its degradation rate. 
143
 Collagen has been used in many types 
of surgery (e.g., plastic surgery), cosmetics, drug delivery, as well as in bioprosthetic 
implants and tissue-engineering of multiple organs.
143
 Collagen has its own 
disadvantages though: depending on how it is processed, it can potentially cause 
alteration of cell behavior (e.g., changes in growth or movement), have inappropriate 
mechanical properties, or undergo contraction (shrinkage).
143,144
 Because cells interact so 
easily with collagen, cells can actually pull and reorganize collagen fibers, causing 
scaffolds to lose their shape if they are not properly stabilized by crosslinking or mixing 
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with another less "vulnerable" material (chitosan, in our case). Exciting research is being 
performed to bind various proteins or growth factors to collagen as signaling molecules 
in order to tailor cell behavior to specific applications of interest.
143
 One may attach 
molecules that encourage cells to grow (e.g. bone morphogenetic proteins), to move, to 
make new blood vessels, to make a certain protein, or to perform many other actions. The 
biocompatibility and high degradation rate of collagen are exploited in this work by 
combining collagen with the chitosan. 
2.7 Composite chitosan-collagen biomaterials 
Initially, chitosan and collagen have been studied as extracellular matrix 
components. Tan et al. observed that overall matrix integrity increased with the 
proportion of chitosan to collagen.
145
 The addition of chitosan greatly influences 
ultrastructure and changes collagen fiber cross-linking, reinforcing the structure and 
increasing pore size.
145
 Although the proliferation of K562 lymphoblasts was inhibited 
with an increasing proportion of chitosan, cell function-based on cytokine-release was 
greatly augmented.
145
 The cell line was inappropriate for bone tissue engineering and the 
gels are non-load bearing. Similarly, Wang et al. demonstrated that human bone marrow 
stem cells, hBMSC can attach and proliferate in three-dimensional matrices composed of 
glyoxal-crosslinked 50/50 chitosan/collagen, and that these hydrogels supported 
osteogenic differentiation in response to stimulation.
146
 Likewise, Wang et al. used beta-
glycerophosphate (beta-GP), an osteogenic medium supplement and a weak base, to 
simultaneously initiate gelation of chitosan-collagen composite materials at physiological 
pH and temperature.
147
 DNA content for adult human bone marrow-derived stem cells 
(hBMSC) encapsulated in such hydrogels increased twofold in materials containing 
collagen. 
147
 Collagen-containing materials compacted more strongly and were 
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significantly stiffer than pure chitosan gels.
147
 The presence of chitosan in materials 
resulted in higher expression of osterix and bone sialoprotein genes in medium with and 
without osteogenic supplements, higher phosphatase activity and calcium deposition in 
osteogenic medium.
147
 Chitosan-collagen composite materials have potential as matrices 




Nitzsche et al. used a suspension-quick-freezing and lyophilization method to 
incorporate nanohydroxyapatite into a polymeric matrix consisting of collagen and 
chitosan.
148
 In vitro and in vivo studies need to be carried out. 
In order to remineralize dentine affected by caries, Xu et al. modified the surface 
of partially demineralized dentine sections, mainly composed of type I collagen, by 
covalent immobilization of phosphorylated chitosan, P-chi on the collagen surface.
149
 
The results indicated that the covalent immobilization of P-chi can significantly induce 
biomimetic deposition of calcium phosphate.
149
 No mechanical testing was carried out. 
Several chitosan cement formulations were prepared, none of which were load-
bearing: Zhao et al. developed a novel human umbilical cord mesenchymal stem cell 
(hUCMSC)-encapsulating, fiber-reinforced injectable calcium phosphate cement (CPCF) 
scaffold, which incorporated calcium phosphate powders, chitosan, and absorbable 
fibers.
150
 The results indicated that the osteogenic media method with hUCMSCs in 
CPCF was promising for bone regeneration, and that hUCMSCs represent a desired 
alternative to the gold-standard bone marrow MSCs because the former do not require an 
invasive procedure to harvest.
150
 Next, the following researchers used tricomponent 
systems with similar composition, but different fabrication method to ours: Lian et al. 
reinforced self-hardened calcium phosphate cement, CPC with collagen-coated chitosan 
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fibres to reach a fiber volume content of 5%.
151
 They achieved compressive strength of 
the CPC-fibre implant fourfold higher than that of the CPC control (33 MPa when the 
strain was 2.4 per cent ).
151
 This value is about 6 x less than that for human bone.
152
 Nine 
cylindrical implants including six CPC-fiber implants were implanted into bone defects 
of nine dogs and were then post-operatively observed.
151
 After 20 weeks in vivo, new 
callus from the healthy tissue of the defect entirely integrated with the CPC-fiber implant 
and new bone was formed as the implant degraded, thus facilitating bone process repair 
in vivo.
151
 Further, Li et al. created a novel salmon calcitonin-loaded bioactive injectable 
calcium phosphate cement for treating an osteoporosis-induced bone defect.
153
 The 
injectable time for the cement is 12 minutes, the compressive strength is low for a load-
bearing application (12 MPa), the final setting time is 40 minutes and the release of the 
containing salmon calcitonin was controlled easily through adjusting the ratio of chitosan 
oligosaccharide and collagen polypeptide.
153
 
Although chitosan and collagen were used in scaffolds with or without growth 
factor delivery, no mechanical testing was performed. For example, chitosan/collagen 
scaffolds  were fabricated by a freeze-drying method and were loaded with VEGF 
protein and adenovirus expressing BMP-2.
146
 The in vitro study revealed a burst and 
rapid release of VEGF with a sustained high-level expression of BMP-2, while the in  
vivo study showed the scaffolds enhanced bone formation, bone-to-implant contact and 
mean peak removal torque when compared to other groups.
146
  
Ravindran et al. developed a novel collagen/chitosan template that is embedded 
within the native extracellular matrix, ECM of differentiating human marrow stromal 
cells (HMSCs) to facilitate osteoblast differentiation.
154
 Gene expression analysis 
showed that the ECM scaffold supported osteogenic differentiation of undifferentiated 
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HMSCs  and the nucleation of calcium phosphate polymorphs to form a mineralized 
matrix, which is promising for bone tissue engineering.
154
 
Recently, Pallela et al. created a scaffold containing chitosan, hydroxyapatite and 
marine sponge collagen using the lyophilization method.
155
 The interconnected porosity 
was 50-170 µm and the human osteosarcoma, MG-63 cell proliferation was higher than 
on pure chitosan, which makes these composite scaffolds promising for matrix-based 
bone repair and bone augmentation. 
Moreover, a new delivery system for multiple bioactive factors and an inductive 
implant scaffold for bone regeneration was invented by Niu et al.
156
 Compared with the 
rapid release from chitosan microspheres (CMs), the bone morphogenetic protein-2-
derived synthetic peptide was delivered from CMs incorporated into 
nanohydroxyapatite/collagen (nHAC), and poly(L-lactide), CMs/nHAC/PLLA 
microsphere-scaffold composite in a temporally controlled manner, depending on the 
degradation of both incorporated CMs and PLLA matrix.
156
 The results indicated that, 
with the appearance of CMs in microsphere-scaffold composite, the MC3T3-E1 
osteoblasts exhibit better morphology and proliferation ability. Moreover, it was 
demonstrated that the CMs/nHAC/PLLA scaffolds possess better biocompatibility in a 6  
mm rabbit femoral condyle defect, which should be attributed to both the incorporated 
chitosan component and the encapsulated bioactive synthetic peptide. 
156
 
Zhang, Wang and coworkers used chitosan (CS) as a dispersant in a bone matrix 
constructed with collagen (Col) and hydroxyapatite (HA).
157,158
 Solid-liquid phase 
separation was used to shape a three-dimensional porous structure to support cell 
growth.
157,158




       
secretion along collagen fibers and the scaffolds repaired a 1.0x.6 cm
2
 bone defect in the 
mandibles of rabbits in 3 months.
157,158
 
All in all, none of the above scaffolds possess load bearing abilities and most of 
them don’t present the degradation needed to see if the scaffolds are suitable for bone 
regeneration.  
2.8 Conclusions 
The above articles summarize the benefits of using chitosan and collagen or 
chitosan, collagen and a crystalline form of calcium phosphate for bone tissue repair: 
osteogenic differentiation of undifferentiated human mesenchymal stem cells, the 
nucleation of calcium phosphate polymorphs to form a mineralized matrix, induction of 
biomimetic deposition of calcium phosphate, better morphology and proliferation ability 
of  osteoblasts, enhanced bone formation, bone-to-implant contact and mean peak 
removal torque, higher expression of osterix and bone sialoprotein genes in medium with 
and without osteogenic supplements, higher phosphatase activity and calcium deposition 
in osteogenic medium and finally, healing a bone defect completely. We hope to adopt a 
similar strategy by preparing composite chitosan-collagen-calcium phosphate 
microspheres using a unique method of incorporating collagen within chitosan 
microspheres via a precipitation method.  The addition of collagen to chitosan and 
calcium phosphate will help increase the degradation rate of chitosan scaffolds without 
compromising the overall mechanical strength.  Although chitosan and the denatured 
form of collagen, gelatin, have been used for cartilage tissue engineering, the addition of 
calcium phosphate can improve the mechanical strength and make the present 
tricomponent scaffolds suitable for bone tissue engineering. Thus, this study would 
provide data on the potential of using a composite chitosan-collagen-calcium phosphate 
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system as a bone graft substitute for bone tissue plerosis for the treatment of non-unions 
and bone defects. 
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Part 1. Microspheres’ Fabrication, Characterization, Degradation and Cell 
Culture. 
Preparation of Composite Chitosan-Collagen-Calcium Phosphate Microspheres 
Chitosan-calcium phosphate and chitosan-collagen-calcium phosphate 
composite microspheres  were made based on the co-precipitation technique, as 
previously described.
33
 To make chitosan-calcium phosphate microspheres, a 2.67 % 
solution of chitosan powder (61% DDA, MW=220 kDa, Primex, Siglufjordur, Iceland) 
was prepared in 2 v/v% acetic acid solution and allowed to dissolve for 24 h. CaCl2 and 
NaH2PO4 were added to achieve a 0.06 M Ca
2+
  and 0.03 M PO4
3-
 with a Ca:P=2. The 
solution was filtered through a nylon mesh with a pore diameter of 180 µm (Gilson 
Company, Inc., Ohio, USA). For the chitosan-collagen-calcium phosphate composites, 
an appropriate volume of 0.03% collagen in 2% CH3COOH was mixed manually with 
the filtered chitosan solution to achieve 10 or 25 wt% collagen. Note: a 3.16 wt% 
chitosan solution was used for making microspheres with 25 wt% collagen.  
Using a KDS 200 two-syringe infusion pump (KD Scientific, Holliston, MA), 
the chitosan solutions were dripped at 4°C through a 21G needle (BD Medical, Franklin 
Lakes, NJ) into a base solution of  20 mass% NaOH, 30% CH3OH and 50% H2O at 
flow rates between 0.15-0.29 mL/min to precipitate the chitosan-based composites into 
beads with a spherical shape. The microspheres were stirred in the base solution for 10-
20 min. before being washed with copious volumes of distilled water, dH2O, until a 
pH=7.4-7.8 was obtained. The last wash was in deionized water, DI H2O. The chitosan-
composite microspheres were air dried in a fume hood overnight.  
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Ash Content for the Determination of Calcium Phosphate in Microspheres 
 
The amount of calcium phosphate salts/mineral present in the microspheres was 
determined using a combustion method.
159
 Approximately 0.5 g beads were weighed and 
heated for about 2 h at 60⁰C under vacuum until the mass change was less than 0.1% to 
remove excess moisture. Clean ceramic crucibles were weighed and placed into a high 
temperature oven at 550±20⁰C for 30 min. The crucibles were allowed to cool in a 
desiccator for 30 min. The crucibles were re-weighed and the heating process was 
repeated until a constant mass for the crucible was reached (<0.1% mass change). The 
microspheres were transferred to a crucible and combusted by placing the crucible over a 
Bunsen burner. The crucibles were then transferred to a high temperature oven at 
550±20⁰C for 3 hours (h). The crucibles were cooled down in a desiccator and the heating 
process was repeated until constant mass was reached (<0.1% mass change). The 
percentage of ash was calculated using the formula: 







Where m0 is the constant mass of the crucible (g), m1 is the mass of the sample (g) 
and m2 is the constant mass of the ash and crucible (g). Three samples were used to 
determine the ash content of each of the three chitosan composite groups plus a control, 
which consisted of chitosan beads with no calcium phosphate to account for salts or other 
impurities in the initial chitosan powder. 
Hydroxyproline Assay for the Determination of the Amount of Collagen Incorporated 
The hydroxyproline assay
160
 was used to estimate the amount of collagen 
incorporated into the microspheres due to the high levels of the amino acid found in the 
collagen polymer. Approximately 0.1 g of each type of composite beads were weighed 
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and heated for about 2 h at 60⁰C under vacuum until the mass change was less than 0.1%. 
This was done to remove excess moisture in the beads. Teflon tape was applied to the 
threads of 2-mL screw cap microcentrifuge tubes (PCR-PT from SARSTEDT, Germany) 
which contained O-rings inside the caps to withstand positive pressure. The beads were 
transferred to the microcentrifuge tubes and approximately 1.9 mL of 6M HCl was added 
to each tube. The tubes were placed in a high heat resistant glass bottle to equalize 
pressure during incubation at 110⁰C for at least 16 h. This was done to hydrolyze the 
proteins into amino acids. After cooling to room temperature, the samples were 
centrifuged for 10 min. at 14,000 RPM to separate particulates from the aqueous solution 
containing hydrolyzed amino acids. 1 mL of the aqueous solution was transferred to a 15 
mL centrifuge tube and 4 mL DI H2O was added. The solution was placed in a -80⁰C 
freezer for at least 1h and lyophilized in a 2.5 L Labconco freeze dryer. The lyophylization 
procedure was repeated in order to remove the residual acid. The resulting hydrolyzed 
amino acid powder was solubilized in 1 mL of DI H2O, vortexed and then a 25 µL aliquot 
was added to a well of a 96-well plate. A 112.5µl volume of chloramine-T reagent was 
added to each test sample and incubated from 20 min at room temperature to oxidize the 
hyroxyproline to a pyrrole derivative. Then 125 µL of Ehrlich’s reagent was added to each 
sample, heated in an oven at 65⁰C for 20 min. to generate a colored chromagen product. 
The absorbance was read at 550 nm. Absorbance was converted to µg/mL hydroxyproline 
using hydroxyproline (Sigma-Aldrich) standards. The collagen concentration was 
calculated taking into account that the measured hydroxyproline is 10.8% in collagen.
161
 
The concentration of collagen in the microspheres was determined based on the mass of 




       
given by the ash content assay. Triplicate samples were measured for each composite 
group. 
Shape Characterization 
Images of the microspheres were obtained with a KEYENCE VHX 1000 digital 
microscope.  40 samples from each group were placed on a weigh boat and viewed with 
a 100x objective eyepiece (200x objective for close-up). Since the microspheres 
exhibited elliptical shapes, the length of the major and minor axis of the microparticles 





X-ray Diffraction Analysis  
To check for the presence of chitosan and calcium phosphate crystalline 
structures composite microspheres were examined by x-ray diffraction using a Bruker 
D8 Advance Diffractometer (Bruker AXS Inc., Madison, WI) using Cu-Kα radiation at 
40 kV and 40 mA.  Prior to XRD analysis, approximately 5 mg of each type of 
microsphere (n=2) were placed in a micro centrifuge tube and then immersed for 5 min. 
in liquid N2. The frozen microspheres were then ground into fine powder using a pestle 
and mortar. The diffraction patterns of the powders were obtained in the scan range 
2θ=5-40⁰ with a step size of 0.04⁰ and a time/step of 0.302 s.   
In Vitro Degradation of Composite Chitosan-Collagen-Calcium Phosphate 
Microspheres 
The in vitro degradation of composite chitosan-collagen-calcium phosphate 
microspheres was based on change in mass over a 6-week period. All the samples were 
gamma sterilized prior to starting the study by irradiating at 32 kGy for 2h. The 
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degradation solution used consisted of 50 µg/mL collagenase type IA (Clostridium 
hystoliticum, Sigma Aldrich) and 100 µg/mL lysozyme in 1x PBS supplemented with 
Penicillin-10,000 IU/mL, Streptomycin-10 mg/mL, Amphotericin B-25 µg/mL. As 
control, microspheres of each type were also incubated in PBS with 
antibiotics/antimycotic (AB/AM) but without enzymes.  
Approximately 30 mg samples (n=4) for each of the composite chitosan-collagen-
calcium phosphate treatment group were weighed and exact mass recorded, and then 
placed in 1.5 mL microcentrifuges. To each sample of microspheres, 1.5 mL of 
degradation solution were added and the samples were placed in an incubator at 37⁰C 
with constant shaking using a plate rocker.  The degradation solution was changed every 
2-3 days in order to avoid the complete loss of enzymes’ activity.  At 1, 3, 5, 7, 14, 21, 28 
and 42 days, the samples were washed with DI H2O five times to remove any precipitated 
salts and proteins before drying in an oven at 40⁰C for at least 24 h. The samples were 
then weighed and the percent change in mass was calculated from the initial mass.  The 
data was reported as percent mass loss ± standard deviation. 
In Vitro Cytocompatibility of Composite Chitosan-Collagen-Calcium Phosphate 
Microparticles and Scaffolds 
The cytocompatibility of the gamma-sterilized composite chitosan-collagen-
calcium phosphate microspheres was evaluated using a murine fibroblast cell line 
(NIH/3T3, ATCC® Number: CRL-1568™) and a human osteosarcoma cell line (Saos-2, 
ATCC® Number: HTB-85™). The cell attachment and growth study was conducted in 
complete growth medium composed of Dulbecco’s Modified Eagle’s Medium with 10% 
FBS and 1x antibiotic/antimycotic for NIH/3T3, and McCoy’s 5A Medium with 15% 
FBS and 1x antibiotic/antimycotic for Saos-2. 
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Briefly, 60 microspheres of each sample group were placed in glass culture tubes, 
13 x 100mm with screw cap (PYREX® Laboratory Glassware, CORNING, MA USA). 
The microspheres were soaked in 200 µL complete growth medium for 3-4 h. Then, the 
medium was removed and 2 mL of medium with cells (3.9 x 10
5
 NIH/3T3 cells/mL or 
1.5 x 10
5
 Saos-2 cells/mL) were added. The tubes were placed in an incubator (Model 
3158, Forma Scientific, Marietta OH) at 37°C and 5%CO2. After 4 h incubation, cell 
attachment to microspheres was measured using the CellTiter-Glo® Luminescent Cell 
Viability Assay (Promega, WI, USA).  The assay estimates number of cells based on the 
presence of ATP via the luciferase-luciferin reaction. The growth medium was replaced 
every 2 days for NIH/3T3 and every 3 days for Saos-2. After 1, 3 or 7 days cell 
proliferation was measured using the CellTiter-Glo® Luminescent Cell Viability Assay. 
The seeding concentration for proliferation for fibroblasts was 1.8 x 10
5
 cells/mL and for 
osteoblasts, 1.2 x 10
5
 cells/mL. The data for attachment was reported as % cell attached 
± standard deviation, while for proliferation the data was reported as # cells 
/microparticle ± standard deviation. 
In addition, at each time point, samples of each chitosan composite 
microsphere were evaluated using a LIVE/DEAD® Viability/Cytotoxicity Kit for 
mammalian cells (Invitrogen Corporation, CA, USA) to determine the viability of 
cells based on plasma membrane integrity and esterase activity of the cells.  
Statistical Analysis 
 
Regression analysis was used for the degradation of microparticles, one-way 
ANOVA & post-hoc tests were used in SigmaStat 3.5 to evaluate the % cell attachment 




       
ANOVA with Tukey’s post-hoc test was used. A p value < 0.05 was considered 
significant. 
 
Part 2. Scaffolds’ Fabrication, Characterization, Physical and Mechanical 
Properties, Degradation and Cell Culture. 
Scaffold Fabrication 
Microspheres for each type of composite were made as described in the section 
“Preparation of Composite Chitosan-Collagen-Calcium Phosphate Microspheres“. To 
make scaffolds, 40 mg beads were fused with 1 drop of either 1 v/v% acetic acid, 
CH3COOH or 2 v/v% glycolic acid, HOCH2CO2H and packed into a cylindrical mold with 
an inner diameter of 6 mm and height of about 15 mm. Scaffolds were gamma-sterilized at 
32 kGy for 2h and kept sealed at room temperature for one week before degradation. The 
scaffolds for cell attachment and proliferation were kept at room temperature for one 
month before the experiments and the scaffolds for mechanical testing were kept at room 
temperature for six weeks before mechanical testing. The scaffolds had a height twice the 
diameter (approximately 14 mm tall by 6 mm diameter) to follow ASTM D695 - 10 
Standard Test Method for Compressive Properties of Rigid Plastics. 
Morphological Characterization 
Images of the scaffolds were obtained with a KEYENCE VHX 1000 digital 
microscope.  The samples (n=5) were placed on a weigh boat and viewed with a 100x 
objective eyepiece (200x objective for close-up). A rough estimate of the size of the pores 
was obtained from the small sequence of images taken (n=5). The longest distance in the 




       
Porosity Determination 
The porosity was determined by liquid volume displacement method using a 
density determination kit (Mettler Toledo, Switzerland), with a Mettler Toledo balance. 
The diameter and height of the cylindrical scaffolds were recorded and methanol was 
poured in the beaker where the gem holder was immersed, to cover the wire basket of the 
gem holder by at least 1 cm. The temperature of the room was recorded in order to have 
the correct value for the density of methanol. The gem holder was attached and the 
balance was tared to read 0. The dry scaffold was placed in the upper cup of the gem 
holder and the mass recorded as mass A in mg. The balance was tared again, the scaffold 
was placed in the beaker and the beaker with methanol and a scaffold were placed under 
vacuum and kept for 4 min. to remove bubbles entrapped in the porous scaffold. The 
scaffold was placed in the wire basket in methanol and the mass, P or buoyancy was 





Where A and P are the masses recorded as indicated above, ρCH3OH is the density of 
methanol, which at 21⁰C is 0.7918 g/cm3. The total volume of the cylindrical scaffold was 








Where D=diameter of the scaffold and H=height of the scaffold.  





Where the mass A and the density ρ are previously defined.  
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This measurement was done for n=10 scaffolds from each group.  
Mechanical Testing  
The compressive modulus of scaffolds was determined using an Instron load frame 
(Model #33R 4465). The scaffolds had a height twice the diameter (approximately 14 mm 
tall by 6 mm diameter) to follow ASTM D695 - 10 Standard Test Method for Compressive 
Properties of Rigid Plastics. A 500 N load cell of the Instron was operated at a rate of 1 
mm/min. The scaffolds were hydrated for 25 h in dH2O prior to testing. The scaffolds were 
conditioned by first compressing samples by 5% of the height, and then unloaded.  Test 
specimens were then compressed up to 50% of the height with Teflon tape above and 
below the scaffold to allow for equal load distribution. The compressive stress and strain 
were recorded and Young’s modulus was calculated for n=10 replicates for each type of 
scaffold.  
In Vitro Degradation of Composite Chitosan-Collagen-Calcium Phosphate scaffolds 
The degradation of the scaffolds was evaluated over a 4 week-period by 
measuring the change in mass at 1 week-intervals. All the samples were gamma 
sterilized at 32 kGy for 2h prior to starting the study. The degradation solution used 
consisted of 50 µg/mL collagenase type IA (Clostridium hystoliticum, Sigma Aldrich) 
and 100 µg/mL lysozyme in 1x PBS supplemented with Penicillin-10,000 IU/mL, 
Streptomycin-10 mg/mL, Amphotericin B-25 µg/mL. As control, scaffolds of each 
type were also incubated in PBS with antibiotics-antimycotic, but without enzymes.  
Samples (n=4) for each of the composite chitosan-collagen-calcium phosphate 
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treatment group were weighed (~ 40 mg) and placed in glass scintillation vials. To each 
scaffold, 3 mL of degradation solution were added and the samples were placed in an 
incubator at 37⁰C with constant shaking using a plate rocker.  The degradation solution 
was changed every 2-3 days in order to avoid the complete loss of enzymes’ activity.  At 
each time point, the samples were washed with 15 mL DI H2O before drying in an oven at 
40⁰C for at least 24 h, weighed and the percent change in mass was calculated.  The data 
was reported as percent mass loss ± standard deviation. 
In Vitro Cytocompatibility of Composite Chitosan-Collagen-Calcium Phosphate 
Scaffolds 
The cytocompatibility of the gamma-sterilized composite chitosan-collagen-
calcium phosphate scaffolds was evaluated using a human osteosarcoma cell line (Saos-
2, ATCC® Number: HTB-85™). The cell attachment and growth study was conducted 
in McCoy’s 5A Medium with 15% FBS and 1x antibiotic/antimycotic. 
Each scaffold (~40 mg) was soaked for 17 h in 2 mL medium in a well of a 24 
well plate so that proteins would attach to scaffolds and the cells wouldn’t fall off during 
the swelling of the scaffolds. The medium was removed, 1.5 mL sterile PBS was added 
so that residual acetic or glycolic acid in the scaffolds will diffuse into the PBS. The 
scaffolds were left in the incubator at 37°C and 5% CO2 for 1 h. They were shaken by 
hand for a few seconds and the PBS was removed and the scaffolds were seeded with 
100 µL with 10
5
 osteoblasts/mL. After 1.5 h, 1 mL medium was added to cover the 
samples in the wells. The medium was replaced every 3 days. Samples were evaluated at 
4 h for cell attachment and at days 1, 3 and 7 for cell proliferation using the CellTiter-
Glo® Luminescent Cell Viability Assay (Promega, WI, USA). For cell attachment, the 
data was reported as mean % cell attachment ± standard deviation, while for cell 
50 
 
       
proliferation, the data was reported as mean # cells/scaffold ± standard deviation. At 
each time point, the samples were examined for viability using a LIVE/DEAD® 
Viability/Cytotoxicity Kit for mammalian cells (Invitrogen Corporation, CA, USA). 
Statistical Analysis 
 
A one-way ANOVA & Tukey’s post-hoc tests were used in SigmaStat 3.5 to 
evaluate the porosity, Young’s modulus and cell attachment.  Regression analysis was 
used for the degradation of scaffolds. For Saos-2 proliferation on scaffolds, a two-way 




















       
CHAPTER 4: RESULTS 
Part 1. Microspheres’ Characterization, Degradation and Cell Culture.  
Representative digital images of the three types of microparticles are shown (Figure 1). 
All microparticles present surface texture.  
 








Figure 1. Digital images of composite chitosan-collagen-calcium phosphate 
microparticles. χtosan-CaP: chitosan-calcium phosphate; 10Coll-χtosan-CaP: 10% 
collagen-chitosan-calcium phosphate; 25Coll-χtosan-CaP: 25% collagen-chitosan-






       
Physicochemical characterization 
The results of the determination of the shape, collagen content and ash content of 
the microparticles are summarized in Table 2. The diameters of the microparticles were 
determined with KEYENCE VHX-1000 digital microscope. Because the particles 
exhibited ellipsoidal shapes, both the major and minor axes were measured. The ratio of the 
major axis to minor axis was used to calculate a sphericity index. The closer the index 
value is to 1, the more spherical the particles tend to be. The sphericity index, close to 1.3 
for all groups, indicates that the microparticles are ellipsoidal and one-way ANOVA 
indicated there was no statistically significant difference in sphericity index between the 
three groups. 
The ash content of the composite microspheres was determined via combustion 
and was used as an estimate of the amount of calcium-phosphate mineral/salt in the 
particles. The ash content of plain chitosan beads without calcium phosphate was 
subtracted from the three experimental composites to account for any residual 
minerals/salts in the starting chitosan material.  
The actual amount of collagen incorporated into the composite microparticles was 
determined based on the hydroxyproline assay. It was found that the microspheres with 
the target 10.0% and 25.0% collagen actually had approximately 2.6% collagen and 7.6% 
collagen, respectively. The hydroxyproline assay for the negative control, chitosan-
calcium phosphate composite beads without collagen, indicated a very low protein 
content, 0.024±0.004%, while the positive control, the collagen stock solution, had 






       
Table 2. Physical and compositional properties of the chitosan-collagen-calcium 
phosphate composite microparticles 
 χtosan-CaP 10Coll-χtosan-CaP 25Coll-χtosan-CaP 
Sphericity Index 1.35±0.21 1.35±0.21 1.31±0.19 
Major axis (µm) 986±118 998±92 937±95 
Minor axis (µm) 736±75 751±103 726±85 
Ash (%) 8.94±0.50 6.77±0.82 9.13±1.16 
Coll 
(%) 
theoretical 0 10.0 25.0 
empirical 0.024±0.004 2.6±0.2 7.6±0.8 
 
X-ray diffraction (XRD) analysis was used to identify crystalline phases present in 
the different microparticle composite formulations. Representative XRD spectra of the 
different composite materials are shown in Figure 2. The peaks at 2θ~11° and 2θ~20° are 
indicative of the hydrous and anhydrous peaks of chitosan respectively.
40
 In the spectra for 
the chitosan-calcium phosphate composite microparticles, two additional peaks at 2θ~32° 
and at 2θ=34.4° were observed. The peak at 2θ~32° corresponds to the (211) plane of 
hydroxyapatite (HA) and the peak at 2θ=34.4°  corresponds to the (220) plane of 
tricalcium phosphate (TCP).
162
 The presence of these peaks indicates that calcium 
phosphate is present partly in crystalline form. With the addition of increasing amounts of 
collagen, both the chitosan and the HA peak at 2θ~32° and TCP peak at 2θ=34.4° reduced 




       
  
Figure 2. Representative XRD spectra of composite chitosan-collagen-calcium phosphate 
microparticles compared with chitosan. A shift in the hydrous peak of chitosan from 
2θ=10⁰ to 2θ=11⁰ is observed, while the anhydrous peak is noticed at 2θ=20⁰. The peak 
at 2θ=32° corresponds to the (211) plane of hydroxyapatite (HA, in green) and the 
peak at 2θ=34.4° corresponds to the (220) plane of tricalcium phosphate
162
 (TCP, 




The total mass loss seen after 6 weeks in both degradation solutions is 
summarized in Table 2. ANOVA analysis indicated that all groups lost significantly 
more mass in the solution with enzymes than in the plain PBS solution. For the 
microparticles in PBS with enzymes (Figure 3) and in the control solution (Figure 4), 
regression analysis showed a significant loss in mass overtime for all composite groups 
















 2θ (degrees) 
χtosan-CaP 
10Coll-χtosan-CaP 
25Coll-χtosan-CaP (211) (220) 
χtosan HA TCP 
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groups (p>0.05). A two-way ANOVA with post hoc test showed there is a statistically 
significant increase in degradation in PBS + enzymes versus the control solution 
(p≤0.001, Table 3). 
 
Table 3. The change in mass of beads in PBS only vs. degradation solution 
respectively, after six weeks. 
 Δmassmicroparticles (%) 
solution χtosan-CaP 10Coll-χtosan-CaP 25Coll-χtosan-CaP 
Control (PBS) 10.0±6.8a 13.2±2.2a 8.3±3.7a 





Figure 3. Degradation of microparticles in PBS + enzymes. Tukey’s test and one-way 
ANOVA showed that all initial masses are statistically different (p<0.05). Regression  


































       
 
Figure 4. Degradation of microparticles in PBS. One-way ANOVA and Tukey’s test 
showed that all initial masses are statistically different (p<0.05). The beads showed a 
loss of mass over time. Regression analysis
163
 showed there were no differences in the 
degradation rate (p<0.05). n=4 
 
Osteoblast and fibroblast attachment and proliferation on microparticles 
Cellular attachment and proliferation studies on microparticles were performed with two 
cell lines: NIH/3T3 murine fibroblasts and Saos-2 human sarcoma osteoblasts.   
For the attachment of both fibroblasts and osteoblasts on microparticles, one-way ANOVA 
analysis, followed by Tukey’s multiple comparison test showed there is no difference in 
percentages of cells attached on the 3 groups of microparticles (Figure 5, 6). More 
fibroblasts than osteoblasts seem to have attached to the microparticles (one-way ANOVA, 





























       
 
Figure 5. Fibroblasts’ attachment (%) on beads. One-way ANOVA analysis, 
followed by Tukey’s and then Bonferroni’s t-tests showed there is no difference 





Figure 6. Osteoblasts’ attachment (%) on beads. One-way ANOVA analysis, 
followed by Tukey’s multiple comparison test showed there is no difference 
between groups for α=0.05 (n=4). 
 
 
Overall, cells proliferated on all treatment groups of microparticles over the 7 day-cell 
culture period, but there was no statistically significant difference between groups for 
fibroblasts (Figure 7) or osteoblasts (Figure 8). At the end of a week, fibroblasts increased 




























































       
  
Figure 7. Fibroblasts’ proliferation on beads. Regression analysis showed no 
significant difference between groups for NIH/3T3 cells (p<0.05), while one-way 
ANOVA showed an increase with time: †=difference between all previous time 
points (p<0.0005), n=4 (except day 1, where n=3 and 10% collagen microparticles 
on day 7, where n=2). 
 
  
Figure 8. Osteoblasts’ proliferation on beads. Two-way ANOVA showed that 
there is a statistically significant increase in osteoblast numbers per day (p<0.001), 
which means that cells proliferate, but there is no difference between the different 
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A representative LIVE/DEAD image of cell viability on constructs, taken using a 
Nikon ECLIPSE TE300 microscope with BIOQUANT OSTEO II software, is shown in 
Figure 9.  
 
Figure 9. Fibroblasts’ viability on 25% collagen-chitosan-calcium phosphate 
microparticles after one week. Light green dots represent fibroblasts. 
 
Part 2. Scaffolds’ Characterization, Physical and Mechanical 
Properties, Degradation and Cell Culture. 
Representative digital images of scaffolds made of the three different bead types 
fused with either acetic acid or glycolic acid are shown (Figure 10). From the small 
sequence of images taken (n=5/scaffold type), the pore size in the gamma-sterilized 
scaffolds is estimated to be between 100-400 µm. Scaffolds fused with acetic acid 
appeared darker brown as compared to the scaffolds fused with glycolic acid, which had a 





       
chitosan right next to where the walls of the mold that held the scaffold were. The sheet 
may result from addition of more acid solution than needed in fusion. 
 
χtosan-CaP 10Coll-χtosan-CaP 25Coll-χtosan-CaP Type of acid 
 
       
                                     
       
       
Figure 10. Digital images of composite chitosan-collagen-calcium phosphate scaffolds: 
100x magnification and close up (200x magnification) to show pore structure. Scale 
shown: 500 µm. 
 
In order to see if the scaffolds may allow cell migration, growth and also allow for 
diffusion of nutrients and waste products, the porosity of the scaffolds was measured using 
a density determination kit. Two-factor ANOVA using the composition of microparticles 
as one factor and the type of acid used for fusing as another factor, indicated that there 









       
differences based on type of acid used for fusing (p=0.3), and there was a significant 
interaction between the composition and type of acid used for fusing (p=0.02). Due to 
interaction, separate one-factor ANOVA’s for the type of fusing acid were performed. 
One-factor ANOVA of acetic acid-fused scaffolds indicated that there was no significant 
difference in the porosity of the scaffolds due to composition (p=0.4). However, one factor 
ANOVA analyses of the glycolic acid fused scaffolds indicated that there was a difference 
in porosity of the scaffolds (p=0.0002). Tukey’s post-hoc test indicated that 25Coll-
χtosan-CaP, gly_ac had higher porosity than the χtosan-CaP, gly-ac group but no 
difference in porosity was observed between the 25Coll-χtosan-CaP and the 10Coll-









       
  
Figure 11. Porosity of scaffolds made of chitosan, 10% collagen or 25% collagen and 
fused with either acetic acid or glycolic acid. Acet_ac: acetic acid; glyc_ac: glycolic 
acid. Two-way ANOVA showed that the porosity of scaffolds among the different 
levels of composition was different (p=0.032), but that based on fusion was not 
statistically significant. The porosity of 25% collagen-chitosan-calcium phosphate 
beads fused with glycolic acid (28.4% mean porosity) is higher than that of 25% 
collagen beads fused with acetic acid and chitosan beads fused with glycolic acid 
(p<0.05). *=difference between groups (p<0.005)  
 
To evaluate the load-bearing capacity of the scaffolds, the mechanical properties were 
determined in compression. A representative stress-strain curve for the scaffolds is 























       
 
Figure 12. Representative stress-strain curve for scaffolds. The two rectangles surround 
linear portions of the curve. 
 
The linear region at strain=0.05 was used to calculate the compressive modulus. 
The 5% strain, which was contained within the first linear region of the stress-strain curve 
of the scaffold, was higher than the maximum strain for the linear region of the stress-
strain curve for bone, 0.7%.
152
 This already shows that the stress-strain curve for the 
scaffold is different than that of bone. The second linear region observed in compression 
tests at higher strains, was associated with the collapse of the composite structure and not 
with the properties of the porous scaffold. Two-factor ANOVA indicated that there were 
significant differences in the  modulus of the scaffolds based on composition, type of 
fusing acid, and that there was a significant interaction between the composition and type 
of fusing acid (p≤0.001). Due to interaction, separate one-factor ANOVA’s based on the 
type of fusing acid were performed. For scaffolds fused with acetic acid, one-way 
ANOVA indicated that there were no statistical differences in modulus of the scaffolds 
based on composition (p= 0.7), but that glycolic acid-fused scaffolds had lower modulus 
than acetic acid-fused scaffolds (p<0.001). For scaffolds fused with glycolic acid, 
ANOVA indicated that there were differences in the modulus of the different scaffolds 
based on composition (p=0.001). Tukey’s post hoc test indicated a significantly higher 
modulus for 10% collagen scaffolds vs. 25% collagen scaffolds and chitosan scaffolds 
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(p<0.001). Consequently, χtosan-CaP, acet_ac, 10Coll-χtosan-CaP, glyc_ac and 25Coll-
χtosan-CaP, acet_ac had the significantly higher E (p<0.05) while there was no difference 
in E between 25Coll-χtosan-CaP or the χtosan-CaP composite groups (Figure 13).  
 
Figure 13. Young’s modulus in compression of composite scaffolds. Acet_ac: acetic 
acid; glyc_ac: glycolic acid. Two-way ANOVA showed that Young’s modulus was 
higher for all three types of microparticles fused  acetic acid than that of microparticles 
fused with glycolic acid (n=10). Error bars are standard deviations. *=difference 
between groups’ means (p<0.001).   
 
Degradation study 
In order to see if fusing the different composite microparticles with acids affects 
the degradation rate, scaffolds of the three bead compositions fused with acetic acid versus 
glycolic acid were degraded in control solution or in degradation solution for 4 weeks.  
The results of the scaffold degradation study after 4 weeks are summarized in 
Table 4. Three-way ANOVA followed by post-hoc tests showed there is no statistically 
significant difference between scaffolds with 10% collagen and chitosan scaffolds, but the 

































       
ones (p<0.001). There is a significant increase in the %Δmass in degradation solution 
versus the control solution (p<0.001). In the degradation solution there is a significant 
group x fusion interaction (p≤0.001) and difference among different groups within acetic 
acid:  25Coll-χtosan-CaP, acet_ ac vs.  10Coll-χtosan-CaP, acet_ ac (p<0.001) and vs. 
χtosan-CaP, acet_ ac (p=0.002) (Table 4). In degradation solution, based on the type of 
acid used for fusion, chitosan and 10% collagen scaffolds fused with glycolic acid 
degraded significantly quicker than those fused with acetic acid.  
 
Table 4. The change in mass of scaffolds fused with either acetic or glycolic acid for PBS 

























control 1.8±0.6 2.4±2.0 1.0±1.1 6.1±5.0 9.4±2.6 2.5±2.8 
enzymes 10.7±2.5 11.5±2.0 18.3±1.2 23.0±2.6 25.8±3.4 21.3±2.5 
 
Regression analysis showed significant increase in the degradation profile (p<0.05) 
in the enzymes’ solution based on composition: chitosan and 10% collagen fused with 
glycolic acid vs. acetic acid (Figure 14). The scaffolds degraded with time. χtosan-CaP, 





       
 
Figure 14. Degradation of scaffolds in PBS + enzymes. 
 
Tukey’s multiple comparison test showed that the initial masses are similar (α=0.05). 
Regression analysis showed degradation rates are significantly higher for:  
 Chitosan fused with glycolic acid vs. chitosan fused with acetic acid (p<0.05) 
 10% collagen fused with glycolic acid vs. chitosan fused with acetic acid 
(p<0.05) 
 Chitosan fused with glycolic acid vs. 10% collagen fused with acetic acid 
(p<0.05) 
 10% collagen fused with glycolic acid vs. 10% collagen fused with acetic acid 
(p<0.05) 
 
ANOVA analysis showed significant interaction or difference in the degradation 
profile in PBS based on acetic acid (Figure 15). It also showed increased degradation with 


































       
10Coll-χtosan-CaP, acet_ac and 10Coll-χtosan-CaP, glyc_ac displayed the highest 
degradation rate: 2.0-2.4 %Δm/day.  
 
 
Figure 15. Degradation of scaffolds in PBS. 
 
Tukey’s multiple comparison test showed that the initial masses of 25% collagen beads 
fused with glycolic acid are significantly higher than chitosan beads fused with glycolic 
acid (p<0.05). 
Regression analysis showed degradation rates are significantly higher for:  
 Chitosan fused with acetic acid vs. 25% collagen fused with acetic acid 
(p<0.05) 
 10% collagen fused with acetic acid vs. 25% collagen fused with acetic acid 
(p<0.05) 





































       
Osteoblasts’ attachment and proliferation on scaffolds 
For osteoblasts attached on scaffolds, the groups were significantly different 
(p<0.05, one-way ANOVA) and Tukey’s test showed a higher attachment for acetic acid-
fusion vs. glycolic acid-fusion of the chitosan microparticles. Post hoc analysis showed 
there was attachment was higher for 10% collagen microparticles fused with glycolic acid 
than both 10% collagen and 25% collagen microparticles fused with acetic acid, and that 
attachment on chitosan microparticles fused with acetic acid was higher than 10% 
collagen microparticles fused with glycolic acid (Figure 16). Chitosan microparticles 
fused with either acid and 25% collagen-chitosan-calcium phosphate microspheres fused 
with glycolic acid displayed the highest cell attachment: 2.7±1.2%.  
   
Figure 16. Osteoblasts’ attachment on scaffolds (n=4, except chitosan-calcium 






































       
Overall, cells proliferated on all treatment groups of scaffolds over the 7 day-cell 
culture period (Figure 17). At the end of a week, osteoblasts proliferated 4-7x on scaffolds 
(only twice on 10% collagen microparticles fused with glycolic acid). Regression analysis 
showed a difference on osteoblasts’ growth based on group for 10% collagen-chitosan-
calcium phosphate scaffolds. Tukey’s multiple comparison test showed significantly 
higher number of osteoblasts/scaffold with time for all scaffolds except for 10% collagen 
microparticles fused with glycolic acid (p<0.05). There were no statistical differences 
between day 1 and day 3 for all scaffold groups except the above-mentioned 10% collagen 
microparticles fused with glycolic acid. Moreover, there was no significant difference 




       
 
Figure 17. Osteoblasts’ growth on scaffolds. Regression analysis showed the number of 
osteoblasts increased with time (p<0.05) and the cell proliferation rate is higher for: 
chitosan fused with acetic acid than 10% collagen fused with glycolic acid; 10% collagen 
fused with acetic acid than 10% collagen fused with glycolic acid; 25% collagen fused with 








































       
CHAPTER 5: DISCUSSION 
 
A bone graft should possess adequate porosity, degradability, biocompatibility and 
initial mechanical strength to provide a framework for cells to attach and proliferate while 
maintaining bone volume/shape.
76
 The predecessors of the present scaffolds showed 
promising results. When compared to plain chitosan scaffolds, the predecessor composite 
chitosan-hydroxapatite scaffolds exhibited rougher surface and greater surface area for cell 
attachment, about 3x higher Young’s modulus and increased pre-osteoblast 
proliferation.
107
 The chitosan-crystalline calcium phosphate scaffolds were tougher and 
more flexible than what has been reported for pure calcium phosphate scaffolds.
107
 







suffered from low degradation and mechanical strength. The mechanical strength of the 
scaffolds was higher than that of hydrated chitosan/collagen hydrogels (18.9 kPa)
147
 and 




Additionally, Reves et al. noticed decreased cytocompatibility with the presence of 
hydroxyapatite (unpublished results).
42
 To overcome these limits and improve on the 
degradation and cytocompatibility of microsphere-based scaffold design, this research 
incorporated collagen, a biodegradable native component of bone that shows excellent 
attachment and interaction with cells,
146,147,151,153-157,166
 into the chitosan-calcium 
phosphate microparticles. Further, for increased mechanical strength, we hypothesized that 
fusion with glycolic acid would melt chitosan-collagen-calcium phosphate beads more 





       
Part 1. Microparticles 
The hydroxproline assay showed that approximately 25.5-30.3% collagen was 
incorporated into beads based on initial collagen amount added to composite solution mix.  
It has been observed that human bone marrow cells attach to and proliferate better 
on rougher hydroxyapatite surfaces as compared smoother surfaces.
167
 The microparticels 
displayed roughness, which may have aided cell attachment. All composite beads 
exhibited an ellipsoidal shape with a sphericity index (i.e. major axis: minor axis) of 
1.3±0.2. We predicted that the surface tension would gather the chitosan-calcium 
phosphate solution drops into spheres. The microparticles looked spherical when hydrated, 
but that was not the case in the dry state. Due to the fact that the microparticles were left in 
precipitating base solution for a short time to prevent the degradation of collagen, there 
was reduced time for induction of chitosan and calcium phosphate crystallinity. The XRD 
spectra did reveal decreases in crystallinity for chitosan and CaP in composites, especially 
as the amount of collagen increased in the formulation. It may be that the microparticles 
flattened out under their own weight during drying.  
An aim of this work was to make composite chitosan-CaP materials with either 
10% or 25% collagen. Compositional analysis based on the hydroxyproline assay for 
collagen and combustion for ash/mineral content indicated that the 10Coll-χtosan-CaP 
particles had actual compositions of 2.6±0.2% collagen, 6.8±0.8% CaP and 90.6±0.8% 
χtosan and that the 25Coll-χtosan-CaP particles had actual compositions of 7.6±0.8% 
collagen, 9.1±1.2% CaP and 83.3±2.0% χtosan.  
For both chitosan-collagen composites, 26-30% of the initial collagen was 
incorporated into the microparticles. The lower incorporation of collagen in the 
microparticles may be due to the following reasons: 1) degradation of collagen in the base 
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solution during the 10-20 min. interval the microparticles were in the highly alkaline pH 
(~13) and 2) the presence of salts in the lyophilized collagen used to make the beads, 
showed by the hydroxyproline assay (10.6%), which was not accounted for when 
calculating the mass of lyophilized collagen needed to make 10 or 25% collagen 
microparticles.  
In determining the mineral content for the composite microparticles due to the 




 salts, it was noted that the chitosan material itself exhibited 
some residual ash content (<0.2%), which was likely due to residual calcium carbonate 
from the processing of the materials from original shrimp shells.
168
 This amount of ash 
though was very small (~100x less) relative to the overall ash content measured for 
composites made with solutions containing calcium and phosphate salts and was not 
considered to add appreciably to the overall mineral component of the composites. All 
composite microparticles were loaded with the same amount of salts. The decreased 
calcium phosphate of the 10% collagen composites shown by the ash content may really 
only be an artifact of the number of washes that were performed  to get the pH 7.4-7.8, 
which could have washed some of the salt away. Hence, all groups were loaded with a 
similar ratio of Ca:P.   
The microparticles’ composition does not reflect the relative percentages of 
components of native bone, except for collagen. Collagen is 19.8-20.1% of bone
47
 and 
10% of adult bone mass is collagen,
169
  which explains why we chose 10-25% collagen. 
Since the mineral part of bone is underrepresented (6.8-9.1%), an area of improvement is 




XRD indicated the presence of crystalline chitosan and crystalline forms of CaP 
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(e.g. a peak for HA at 2θ=32° with other peaks masked in the background: 2θ=26° and 
2θ=40°, and a peak at 2θ=34.4° for TCP). This indicated that even though the beads were 
in precipitating solution for a short time, there was some induction of crystalline forms 
(the chitosan and HA peaks are similar to those observed by Reves
66
). The relatively lower 
intensity of the CaP crystalline peaks as compared to those seen by Chesnutt
40
 is reflective 
of the lower concentration of crystalline CaP forms which is attributed to the short time in 
base solution. The XRD spectra were noisy due to the presence of chitosan. It was 
observed that with addition of 10 mass% collagen to the composite, crystalline peaks for 
chitosan (2θ=12°, hydrous peak and 2θ=20°, anhydrous peak) and HA/TCP decreased and 
disappeared in the 25% collagen composite microparticles. Consequently, the collagen-
containing microparticles are more amorphous than chitosan itself, despite chitosan being 
a crystalline polymer.
170
 This suggests that the addition of collagen interfered with or 
inhibited the formation of chitosan and CaP crystalline structures. This effect has been 
seen by others, e.g. Chen et al.
171
 
In vitro degradation was due to simple hydrolysis and leaching of calcium 
phosphate salts/minerals. The degradation was 2.5 times greater in solutions with enzymes 
as compared to the control solution without enzymes. This was expected since the 
lysozyme and collagenase are the main degradation mechanisms for chitosan and collagen, 
respectively. However, it appeared that there was no statistically significant difference in 
degradation rates between different microparticles in either the control or the enzyme 
degradation solutions. This was contrary to our proposed hypothesis that collagen would 
increase degradation. Nevertheless, it was important that the degradation of the 
microparticles increased to 20% after 6 weeks. At two weeks, the mass loss of chitosan 
beads was 12.5%, 6.25 times higher than that observed by Chesnutt (who saw only 2% 
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mass loss over 2 weeks in PBS with 5 times higher lysozyme concentration)
107
 and Reves, 
who did not see mass loss over a month.
66
 The mass loss of beads at two weeks was 
similar (although slightly smaller) to that of chitosan beads without calcium phosphate 
prepared by Mecwan (~15%).
89
 The higher degradation rate may be attributed in part to 
the reduced crystallinity of 61% DDA chitosan compared to the 92.3% DDA chitosan 
employed by Reves and Chesnutt. The low degree of deacetylation chitosan degrades 
faster than high DDA chitosan due to looser chain packing of the polymer, making the 
polymer chains more susceptible to enzymatic degradation by lysozyme.
66
 It is noted that 
the chitosan-calcium phosphate microspheres prepared by Chesnutt et al. exhibited a high 
chitosan crystallinity index of ~80%.
107
  The degradation of the composite microspheres in 
this study after one month, 15.1±8.5%, was intermediate when compared to those reported 
for several types of chitosan/β-TCP/PMMA microspheres prepared via a emulsion method 
by Lin L-C et al. which exhibited between 4 and 31% mass loss, with the higher mass loss 
associated with lower PMMA.
172
 However, Lin et al.’s microspheres-cement constructs 
exhibited a low porosity and no cytocompatibility is assessed. In another study by Yan et 
al., after cross-linking with 0.5% genipin, the degradation degree of 1:1 collagen:chitosan 
scaffolds was below 1% in 100 µg/mL collagenase after 12 h,
173
 which would project to 
complete degradation in two months. However, the concentration of the collagenase 
solution was twice than that used in the present study and no lysozyme was used. The 
limitation of their study was the storage modulus of the collagen-chitosan scaffolds, which 
is almost 24000x lower than that of bone, 11 GPa.
174
 
In vitro cell viability studies on composite microparticles were conducted to 
observe cytocompatibility. In this study, fibroblast attachment to the microparticles 
averaging 40.6±8.0% was similar to 42.21±9.15% HEPM cell attachment to Reves’ 
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microsphere-based scaffolds
66
, but was lower than the 60% attachment observed by 
Chesnutt,
107
 which is considered good cell attachment. The osteoblast attachment to the 
microparticles, 25.8±8.3% was lower than the fibroblast and HEPM cell attachment. There 
was no difference in the attachment or growth of fibroblasts and osteoblasts between the 
different composite microparticles. This was contrary to the proposed hypothesis that the 
addition of collagen would improve both cell attachment and growth. It is noted that 
attachment and proliferation of fibroblasts was greater than that of osteoblasts, but this is 
likely due to the difference in initial cell seeding densities, since fibroblasts were seeded at 
a higher concentration than osteoblasts. LIVE/DEAD assay confirmed the presence of 
cells, although it wasn’t able to show proliferation for all groups. All cells proliferated in 
time based on the CellTiter-Glo® Luminescent Cell Viability Assay. The highest cell 
increase after a week was seen in fibroblasts on beads, followed by osteoblasts on beads. 
The fibroblast proliferation from day 1 to day 7 was 6 fold and the osteoblast proliferation 
was ~4 fold, compared to 1.6, 1.5 and 1.9 fold proliferation for MC3T3-E1 on chitosan, 
collagen/chitosan, TGF-β1-loaded collagen/chitosan microgranules, respectively.
175
 The 
one-week cell proliferation in this study is higher than the two-week proliferation of 
MG63 osteoblast-like cells cultured on collagen–nanohydroxyapatite beads: 1.33x.
97
 The 
fibroblasts and osteoblasts showed adequate proliferation when compared to other cells on 
substrates with maximum two out of three components of the present microparticles.
97,175
 
We can conclude that the composite microparticles show improved cytocompatibility. 
 
Part 2. Scaffolds 
To make 3D scaffolds, microparticles were fused together by adding dilute acetic 
or glycolic acid to make the outer surfaces sticky, and then the microparticles were loosely 
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packed together and allowed to dry. The porosity and pore sizes of the scaffolds were 
determined based on the Archimedes’ principle and by analyzing images of scaffolds, 
respectively. The porosity of the scaffolds was found to range from 19.4±2.6 to 23.4±6.3% 
and there were no differences based on either the composition of the particles or the type 
of fusing acid used. This porosity is lower than that reported for other microparticle-based 
scaffolds: 33.7±5.2–35.8±2.1%.
40,42
 The lower porosity is largely attributed to the 
ellipsoidal shape the microparticles. It has been suggested that a minimum of 30% 
porosity is needed to provide sufficient space for bone/tissue ingrowth.
80
  Improvement in 
the shape and/or fusing of the particles will be needed to achieve this minimum porosity 
threshold.  
Nevertheless, pore sizes for all scaffolds were found to range from 100-400 µm 
which are similar to pore sizes reported for other microparticle-based scaffolds (100-800 
µm in diameter
66,107
) and above the minimum 50 µm size reported as needed for 
osteogenesis.
66
 Thus, while the porosity of the scaffolds should be increased, the overall 
pore size is adequate for bone tissue engineering applications.  
With regard to color hue perception, the darkening of the scaffolds may be an 
effect of γ-sterilization. 
Ideally, bone scaffolds should be able to bear compressive loads and have enough 
porosity to allow bone ingrowth and still provide mechanical stability. High levels of 
porosity cannot be reached without compromising mechanical stability of the chitosan 
scaffolds. It was suggested that the porosity of bone scaffolds be at least 30%.
80
 Knowing 
that cancellous bone consists of 30% bone and 70% void volume, the scaffolds should 
have about 30% porosity to allow for native bone ingrowth, while the scaffolds degrade in 
time.176 If needed, the porosity can be increased by making the microparticles spherical. 
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Spherical beads can be obtained by lowering the dripping rate on the syringe pumps or by 
reducing the volume of acid added to fuse the beads. Less acid for fusion would result in 
less bead fusion and larger pores. The porosity of the collagen-chitosan-calcium phosphate 
scaffolds was not affected by the acids used to fuse the beads in this study and was slightly 
lower than that of chitosan/PLAGA sintered microsphere scaffolds (~35%)
177
 and lower 
than that of other rapid prototyped, lyophilized or other porous formed chitosan-based 
scaffolds.
90,92,95,96,155
 Higher porosity facilitates bone ingrowth better, but that comes with 
a cost: decreased stiffness. 
Young’s modulus was computed from the lower linear region of the stress-strain 
curve because that pertains to the compression of the scaffold with pores (a bone graft 
structure that will be seen by bone in vivo). The two values for strain were chosen to be 
below the yield strain for bone.
152
 Even though bone is linearly elastic up to strain of 0.7% 
and yields plastically at strains of about 3%,
152
 the strain values were chosen to be ε=5% 
and 10% because they fall in the first linear region of the stress-strain curve for the 
scaffolds. Only Young’s modulus at 5% strain is presented. Glycolic acid-fused scaffolds 
exhibited lower Young’s modulus except for 10% collagen. The packing of the 
microparticles is one of the factors influencing stiffness. Glycolic acid, which is stronger 
than acetic acid and whose concentration was twice that of acetic acid in this study, may 
have dissolved chitosan and collagen too much, resulting in a weaker structure. The values 
of Young’s modulus of the present scaffolds are about 10 times lower than the inferior 
limit of the range of compressive elastic modulus reported for cancellous bone: 10-2000 
MPa.
43
 This implies that these scaffolds will need further improvement to be load-bearing. 
Even though the moduli of the scaffolds from this study are 9 times lower than those 
obtained by Chesnutt et al.,
40
 9.29±0.8 MPa for rehydrated chitosan-calcium phosphate 
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scaffolds, the 20x greater degradation rate of the present scaffolds compensates for the 
lower Young’s modulus. In addition, after a month, new bone should infiltrate the scaffold 
and start taking a part of the load that was originally only on the scaffold.
55,57
 Young’s 
modulus, E, of the present scaffolds is lower than some bone regeneration biomaterials 
containing CaP, PLAGA or PCL
29,32,90,121,172
 and higher than that of hydrated 
chitosan/collagen hydrogels (18.9 kPa)
147
 (Table 5). Some of the Young’s modulus values 
will be over-estimated in case of the dry samples (non-physiologically relevant). 
 
Table 5. Young’s modulus of various bone scaffolds. 





Hydrated chitosan-calcium phosphate 
scaffolds 
9.29±0.8  Chesnutt et al.
40
 
Hydrated CaP/polyurethane composites 2500-3600 Yoshii et al.
29
 
Dry chitosan/β-TCP microspheres in 
PMMA cement 
400-1200 Lin et al.
172
 
Dry rapid prototyping-PCL scaffolds  
 
12.5 ± 2.3 in tension Ahn et al.
90
 
Dry porous sintered microsphere scaffolds 






Dry electrohydrodynamic –PCL scaffolds  6.3 ± 1.8 in tension Ahn et al.
90
 
Dry chitosan/HA nanocomposites in 50–50 
ratio  
17560 Verma et al.
32
 
Dry polygalacturonic acid/HA 
nanocomposites in 50–50 ratio   
29810 Verma et al.
32
 
Dry chitosan/HA/polygalacturonic acid 
nanocomposites  
23620 Verma et al.
32
 




In vitro degradation studies were conducted on scaffolds to investigate the effect of 
collagen on the degradation profile. At most 9.4±2.6% degradation of scaffolds was 
observed in solutions without enzymes, whereas in solutions with enzymes, degradation 
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was 2-2.5x greater (25.8±3.4%), indicating that enzymes would affect degradation. 
Similar to the microparticles, it does not appear that composition had any affect, but it 
does appear that the type of fusing acid did, with the glycolic acid-fused constructs having 
greater mass loss than the acetic acid-fused scaffolds. The degradation is higher than that 
of lysine-triisocyanate-based polyurethane-CaP (PUR) composites: PUR/HA-12% after 6 
weeks and PUR/TCP-5% after 6 weeks,
29
 porous sintered microsphere scaffolds based on 
cellulose derivatives-10–15% after 24 weeks.
121
 The degradation of scaffolds in the 
control solution may be due to the following processes: dissolution of salts and simple 
polymer hydrolysis. The two processes plus enzymatic hydrolysis of the polymers occur in 
the lysozyme and collagenase solution, which almost tripled the mass loss. Jiang et al. 
reported that chitosan-PLGA sintered microsphere-based scaffolds had ~0.5wt% loss, 
three times lower than the 1.5wt% loss seen for PLGA sintered scaffolds after 12 weeks of 
degradation.
177 
This shows the interaction between the polymers: the increase in chitosan 
content decreases the degradation rate of the chitosan-collagen-based scaffolds. On the 
contrary, the results of our study do not support any interaction between chitosan and 
collagen polymers that can influence degradation.  
In vitro cell viability studies on scaffolds were conducted to observe if there were 
any cytotoxic effects with the increased calcium content and type of acid used for fusion 
of scaffolds. In terms of cell attachment, osteoblasts grew more on chitosan 
microparticles fused with acetic acid and 25% collagen microparticles fused with glycolic 
acid than the other 4 groups (p<0.05). The cell attachment was lower than that of HEPM 





), but this may be explained by the 10x higher initial cell seeding 
concentration in the last two studies. The initial % of cells attached can be explained by 
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the initial cell seeding concentration. The seeding concentration was 43.1 times lower 
than for NIH-3T3 fibroblasts on beads. Additionally, the initial % of cells attached can be 
explained by the fact that the pores of the scaffolds may have been filled with medium 
before the pipetting of the cells, leaving cells to attach only to the surface of the scaffolds. 
Moreover, two factors can explain the low cell attachment: the pull of gravity of cells 
toward the bottom of the well where each scaffold lay and the propensity of cells toward 
tissue culture plastic compared to the scaffold material. Shaking scaffolds of medium 
before pipetting the cells may have increased the cell attachment, because cells would 
have gone through the scaffold pores and spent more time, which meant more cells could 
attach before being pulled by gravity toward the tissue culture plastic-bottom of the well.  
LIVE/DEAD assay confirmed the presence of cells, although it wasn’t able to 
show proliferation for all groups. In spite of osteoblasts growing on scaffolds, their low 
initial seeding concentration (9.1 x 10
3
 cells/mL) and the fact that the scaffolds weren’t 
shaken to leave the pores free of medium before seeding with cells gave misleading 
LIVE/DEAD images with low cell numbers (not presented). The cells didn’t completely 
cover the scaffolds. All cells proliferated in time, as shown by CellTiter-Glo®, although 
10% collagen beads fused with acetic acid showed a slight decrease in number on day 3, 
but increased in number on day 7. The cells proliferated approximately 7x in a one-week 
period. Looking at proliferation of osteoblasts or osteoblast-like cells on other bone 
regeneration biomaterials, the proliferation of osteoblasts in the present study is better than 
the average (higher than proliferation in 80% of the studies below), as it is higher than 
scaffolds that contain CaP in the form of apatite or TCP, collagen, gelatin, chitosan
29,40,92-
94,96,156
 and smaller than the proliferation of scaffolds composed of chitosan, CaP in the 
form of HA or PCL
90,155
 (Table 6).  
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PLLA scaffolds coated with 
apatite/collagen 










CMs (chitosan microspheres)/nHAC/PLLA 
scaffolds  










SBF-treated HA-added microporous PCL 
scaffolds 





chitosan-calcium phosphate composite 
scaffolds 




















chitosan-HA-marine sponge collagen 
scaffolds 











Collagen addition did not impact bead degradation and cell attachment and 
proliferation, so χtosan-CaP, 10Coll-χtosan-CaP and 25Coll-χtosan-CaP are viable 
microparticles for use as building blocks in bone grafts, ligaments or tissue fillers. 
In order to determine which scaffold combination provides the best bone graft, cell 
proliferation was considered as the primary factor in ranking scaffolds, Young’s modulus 
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was the second factor and the degradation in PBS+enzymes was the third factor. Cell 
attachment and porosity were considered as less important factors and are presented for 
informative purposes, since cell proliferation is more important than attachment and cell 
viability should explained by the porosity. Ranking of the scaffolds is presented in table 7. 
 
Table 7. Ranking of the scaffolds based on top three factors. +++means best or 
belongs to group 1 (as mentioned earlier) and + denotes the lowest outcome or belongs to 
group 3. 
 
In summary, chitosan-calcium phosphate and 25% collagen-chitosan-calcium 
phosphate beads fused with acetic acid seem the most suitable bone graft. They are 
followed by: χtosan-CaP, glyc_ac; 10Coll-χtosan-CaP, acet_ac, 10Coll-χtosan-CaP, 


























+++ +++ +++ ++ + ++ 
Young’s 
modulus 
++ + ++ + ++ + 
Degradation + + + ++ ++ + 
Cell 
attachment 
++ + + ++ ++ ++ 
Porosity ++ ++ ++ + ++ ++ 
Ranking ① ② ① ② ② ③ 
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performed worse as a potential bone graft, but all formulations show promise in bone 
tissue engineering. 
If any of the formulations for scaffolds have to be chosen for further research, 
based on Young’s modulus, the best scaffolds would be the ones fused with acetic acid 
and 10% collagen fused with glycolic acid. Based on degradation, the scaffolds fused with 
glycolic acid degrade almost 2x as fast than the ones fused with acetic acid. Since cells 
proliferate on all scaffolds and the number of cells that landed on the scaffold may differ, 
the scaffolds may be considered similar in proliferation. Following this rationale, since 
proliferation seems similar, the best scaffold in terms of degradation and stiffness would 
be 10% collagen-calcium phosphate-chitosan microparticles fused with glycolic acid. 
Lastly, it would be of interest to increase Young’s modulus to make the scaffolds load-
bearing. 
Furthermore, with the current mechanical properties and degradation profile, the 











       
CHAPTER 6: CONCLUSIONS 
 
In this preliminary study, the design criteria were to improve the degradation of 
previous chitosan-CaP microsphere-based scaffolds, perhaps improving cytocompatibility 
and mechanical properties. To meet these design criteria, three composite microparticle 
formulations with chitosan, calcium phosphate and variable percentages of collagen were 
made by precipitation. These composite microspheres were evaluated in vitro for their 
potential as bone tissue fillers. The microparticles were fused with either acetic or 
glycolic acid and evaluated in vitro as potential bone scaffolds.  
It was found that the microspheres with the target 10.0% and 25.0% collagen 
incorporated only about 30% of the theoretical collagen. XRD analysis indicated that 
chitosan and the crystalline form of calcium phosphate, HA, is present, as well as TCP.  
All bead types degraded approximately 20% within 6 weeks, which predicts 
degradation within 8 months, below the 13 month-remodeling phase and maturation of 
bone.
46
 More NIH/3T3 fibroblasts than Saos-2 osteoblasts attached to the beads during 
the 7-week culture period with no difference between microparticle types, which showed 
good attachment, cytocompatibility and proliferation. Consequently, the data do not 
support the hypothesis because the addition of collagen did not enhance degradation and 
cytocompatibility of the microspheres. The proliferation was higher than in other 
studies.
97,175
 Hence, all bead formulations (with and without collagen) may be used as 
tissue fillers in craniofacial defects, osteoporosis or at the interface between bone and 
ligament or bone and tendon, or potentially as ligament replacement (in a different shape, 
of course). 
The scaffolds were made from the three types of microparticles and fused with 
two acids to evaluate differences in porosity, mechanical properties, cell attachment and 
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proliferation. We demonstrated that, in spite of the overall decreased scaffold porosity 
(~19-28%), the remaining pores were of adequate size for cell penetration. The at least 
quadruple growth of osteoblasts on scaffolds stands as evidence for the biocompatible 
properties of the composites. Glycolic acid-fused scaffolds exhibited lower Young’s 
modulus except for 10% collagen than acetic acid-fused scaffolds (E~1 MPa) at 5% 
strain. Young’s moduli for all scaffolds were about 10 times lower than the inferior limit 
of the range of compressive elastic modulus reported for cancellous bone: 10-2000 
MPa,
43
. All scaffolds, regardless of composition, displayed ~20% degradation in one 
month, which prognosticated a 6-month dissolution. Moreover, all osteoblasts attached 
and proliferated approximately 7x in a one-week period, which was higher than the 
proliferation seen in several other studies.
29,40,92-94,96,146,147,156,157
  
The addition of collagen to the microsphere-based scaffolds did not affect 
degradation, cytocompatibility or Young’s modulus, which means that the hypothesis was 
not supported. Collagen may not have had an effect due to the low collagen incorporation 
(at most 7.6% collagen when compared to the mass of collagen and chitosan). In 
conclusion, the collagen-chitosan-calcium phosphate scaffolds are promising candidates 














       
CHAPTER 7: FUTURE WORK 
 
The results of this study showed about 30% incorporation of collagen in the 
microspheres. One recommendation would be to look for ways of attaching collagen to 
chitosan to favor higher retention. Another recommendation would be to use an 
alternative base solution that will not degrade collagen. 
The microparticles’ composition does not reflect the relative percentages of 
components of native bone. Only collagen follows closely bone composition. Collagen is 
19.8-20.1% of bone
47
 and 10% of adult bone mass is collagen,
169
  while we chose 10-25% 
collagen. Another recommendation is to use a porous hydroxyapatite instead of calcium 
phosphate and to increase its mass at the loss of chitosan to replace the mineral part of 
bone (69% by mass)
47
 and provide higher Young’s modulus to make the scaffolds load-
bearing. 
Knowing that cancellous bone consists of 30% bone and 70% void volume, the 
scaffolds should have about 30% porosity to allow for native bone ingrowth, while the 
scaffolds degrade in time.176 The porosity of the collagen-chitosan-calcium phosphate 
scaffolds can be increased by making the microparticles spherical. Spherical beads can be 
obtained by lowering the dripping rate on the syringe pumps or by reducing the volume of 
acid added to fuse the beads.  
One approach to obtain higher cell attachment on scaffolds (if other cells, such as 
mesenchymal stem cells are to be tested) is to seed scaffolds with a higher cell 
concentration (in the range of 10
5 
cells/mL). Shaking scaffolds of medium before 
pipetting the cells may increase the cell attachment, because cells would spend more time 
through the scaffold pores, which means more cells can attach before being pulled by 
gravity toward the tissue culture plastic-bottom of the well where the scaffolds are kept. 
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Additionally, the scaffolds can serve as anterior cruciate ligament, ACL, 
replacement. For this purpose, the solution would have to be dried in strands that mimic 
the anatomy of ligaments and tested in tension. 
Moreover, different techniques (for example, HNO3) can be explored for fusing 
these composite collagen-chitosan-calcium phosphate microspheres into 3D bone 
scaffolds.  It would be of interest to conduct a long-term degradation study on these 
composite bone scaffold constructs fused by different techniques to evaluate their 
mechanical integrity over the degradation time period.  Likewise, of interest would be the 
evaluation of the pattern of long-term cell growth on the composite collagen-chitosan-
calcium phosphate scaffolds in terms of bone cell morphology, gene expression and 
mineralization markers, such as alkaline phosphatase, calcium content, collagen type I and 
II, osteopontin, osteocalcin and bone sialoprotein. 
The long-term ambition of this work is the implementation of at least one of these 
types of microparticles and scaffolds as a medical device for use in the clinical setting. 
Prior to that, the scaffolds should be evaluated for bone-forming properties for at least four 
months in a Sprague-Dawley rat model. The microspheres can be inserted to fill a 
calvarial defect, while the scaffolds can be inserted in a critical-sized defect in a rat femur. 
Histology may be used to assess the ability of the biomaterials to aid in bone plerosis and 
larger animals may be used prior to human assessment in clinical trials. 
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Figure 1. Degradation of microparticles in PBS + enzymes. Tukey’s test and one-way 
ANOVA showed that all initial masses are statistically different (p<0.05). Regression 




Table 1. Regression lines of the degradation of microparticles in PBS + enzymes. There 





χtosan-CaP 0.3820 Y=0.2965x+6.4989 
10Coll-χtosan-CaP 0.5217 Y=0.3336x+5.9993 































Figure 2. Degradation of microparticles in PBS (control). One-way ANOVA and 
Tukey’s test showed that all initial masses are statistically different (p<0.05). The beads 
showed a loss of mass over time. Regression analysis
163
 showed there were no 




Table 2. Regression lines of the degradation of microparticles in PBS. There is no 





χtosan-CaP 5E-5 Y=-0.0024x+6.0286 
10Coll-χtosan-CaP 0.1446 Y=0.1332x+5.0050 
25Coll-χtosan-CaP 0.0285 Y=0.0664x+2.7645 
 
Table 3. Cell attachment on microparticles. 
 Cell attachment (%) 
Microparticles χtosan-CaP 10Coll-χtosan-CaP 25Coll-χtosan-CaP 
fibroblasts 40.6±8.0 38.5±6.8 43.2±8.7 































The results of the proliferation study are summarized in table 4. 
Table 4. Cell proliferation on microparticles on the last day of proliferation 
 # cells/microparticle 
Microparticle
s 
χtosan-CaP 10Coll-χtosan-CaP 25Coll-χtosan-CaP 
fibroblasts 5744±1343 6324±792 5536±1077 
osteoblasts 4965±1459 4910±359 5579±1173 
 
Table 5. Regression lines of fibroblasts’ proliferation on microparticles. There is no 





χtosan-CaP 0.8691 Y=787.34x+170.04 
10Coll-χtosan-CaP 0.9717 Y=846.47x+443.64 








Figure 3. Regression for fibroblasts’ proliferation of microparticles. There is no 
statistically significant difference in the proliferation rate (α=0.05). 
 
 
































































































































APPENDIX B: YOUNG’S MODULUS, DEGRADATION AND VIABILITY OF 
OSTEOBLASTS ON SCAFFOLDS 
 
  
Figure 6. Young’s modulus in compression of composite scaffolds for ε=0.1 (n=10). 
Acet_ac: acetic acid; glyc_ac: glycolic acid. Two-way ANOVA showed that all three 
types of microparticles fused  acetic acid differ from those fused with glycolic acid. Error 
bars are standard deviations. *=difference between groups (p<0.001).   
 




Regression lines Statistical 
significance in slope 
1=χtosan-CaP, acet_ac 0.9302 Y=4.0960 x-4.9639 1 vs. 2 (p<0.05) 
2=χtosan-CaP, glyc_ac 0.8822 Y=6.5865x-1.9860 1 vs. 4 (p<0.05) 
3=10Coll-χtosan-CaP, acet_ac 0.6220 Y=3.4877 x-2.2552 2 vs. 3 (p<0.05) 
4=10Coll-χtosan-CaP, glyc_ac 0.8648 Y=6.4632x-0.9183 3 vs. 4 (p<0.05) 
5=25Coll-χtosan-CaP, acet_ac 0.6453 Y=4.4350 x+2.9949  













































Figure 7. Degradation of scaffolds fused with acetic vs. glycolic acid in PBS + enzymes. 
N=4 
 




Regression lines Statistical 
significance in slope 
1=χtosan-CaP, acet_ac 0.8857 Y=2.0398x-6.0857 1 vs. 5 (p<0.05) 
2=χtosan-CaP, glyc_ac 0.6407 Y=2.1123x-3.5685 3 vs. 5 (p<0.05) 
3=10Coll-χtosan-CaP, acet_ac 0.5933 Y=2.3998x-5.7657 4 vs. 5 (p<0.05) 
4=10Coll-χtosan-CaP, glyc_ac 0.6851 Y=2.4057x-2.7063  
5=25Coll-χtosan-CaP, acet_ac 0.0599 Y=0.6124x+0.9824  
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Figure 8. Degradation of scaffolds fused with acetic vs. glycolic acid in PBS. N=4 
 




Regression lines Statistical 
significance in slope 
1=χtosan-CaP, acet_ac 0.6633 Y=1670.2x-913.08 1 vs. 4 (p<0.05) 
2=χtosan-CaP, glyc_ac 0.5644 Y=1219 x-370.6 3 vs. 4 (p<0.05) 
3=10Coll-χtosan-CaP, acet_ac 0.6481 Y=1474.7 x-654.68 4 vs. 5 (p<0.05) 
4=10Coll-χtosan-CaP, glyc_ac 0.4018 Y=574.48 x+1802.4  
5=25Coll-χtosan-CaP, acet_ac 0.5162 Y=2410.5 x-1033.4  
6=25Coll-χtosan-CaP, glyc_ac 0.5910 Y=1493.8 x+779.79  
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Figure 11. Osteoblasts’ viability on scaffolds fused with glycolic acid. 
 
 
 
 
